Method of Predicting Obesity Comprising Measuring Neurotensin by Evers, B. Mark et al.
University of Kentucky 
UKnowledge 
Surgery Faculty Patents Surgery 
11-12-2019 
Method of Predicting Obesity Comprising Measuring Neurotensin 
B. Mark Evers 
University of Kentucky, mark.evers@uky.edu 
Jing Li 
University of Kentucky, jing.li@uky.edu 
Paul Dobner 
University of Massachusetts 
Olle Melander 
Lund University, Sweden 
Follow this and additional works at: https://uknowledge.uky.edu/surgery_patents 
 Part of the Neurosciences Commons, and the Surgery Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Recommended Citation 
Evers, B. Mark; Li, Jing; Dobner, Paul; and Melander, Olle, "Method of Predicting Obesity Comprising 
Measuring Neurotensin" (2019). Surgery Faculty Patents. 11. 
https://uknowledge.uky.edu/surgery_patents/11 
This Patent is brought to you for free and open access by the Surgery at UKnowledge. It has been accepted for 
inclusion in Surgery Faculty Patents by an authorized administrator of UKnowledge. For more information, please 
contact UKnowledge@lsv.uky.edu. 
c12) United States Patent 
Evers et al. 
(54) METHOD OF PREDICTING OBESITY 
COMPRISING MEASURING NEUROTENSIN 
(71) Applicants:University of Kentucky Research 
Foundation, Lexington, KY (US); 
University of Massachusetts, 
Worcester, MA (US); Lund University, 
Malmo (SE) 
(72) Inventors: B. Mark Evers, Lexington, KY (US); 
Jing Li, Lexington, KY (US); Paul 
Dobner, Worcester, MA (US); Olle 
Melander, Malmo (SE) 
(73) Assignees: University of Kentucky Research 
Foundation, Lexington, KY (US); 
University of Massachusetts, Boston, 
MA (US) 
( *) Notice: Subject to any disclaimer, the term ofthis 
patent is extended or adjusted under 35 
U.S.C. 154(b) by O days. 
(21) Appl. No.: 15/443,266 
(22) Filed: 
(65) 
Feb. 27, 2017 
Prior Publication Data 
(60) 
(51) 
(52) 
(58) 
(56) 
US 2017/0248610 Al Aug. 31, 2017 
Related U.S. Application Data 
Provisional application No. 62/299,688, filed on Feb. 
25, 2016. 
Int. Cl. 
GOIN 33/68 
A61K 38/00 
C12N 151113 
C12Q 116883 
U.S. Cl. 
(2006.01) 
(2006.01) 
(2010.01) 
(2018.01) 
CPC ......... GOIN 33/6893 (2013.01); A61K 38/00 
(2013.01); C12N 151113 (2013.01); C12Q 
116883 (2013.01); Cl2N 2310/14 (2013.01); 
Cl2Q 2600/158 (2013.01); GOIN 2333/912 
(2013.01); GOIN 2440/14 (2013.01); GOIN 
Field of Classification Search 
None 
2800/50 (2013.01) 
See application file for complete search history. 
References Cited 
U.S. PATENT DOCUMENTS 
8,476,221 B2 
2005/0233393 Al 
2008/0065136 Al 
2010/0256055 Al 
2011/0046956 Al 
2013/0323760 Al 
7/2013 Ghatnekar et al. 
10/2005 Edwards 
3/2008 Young 
10/2010 Castaigne 
2/2011 Auburn et al. 
12/2013 Kang 
I 1111111111111111 1111111111 111111111111111 111111111111111 111111111111111111 
US010473670B2 
(IO) Patent No.: US 10,473,670 B2 
Nov. 12, 2019 (45) Date of Patent: 
EP 
WO 
WO 
WO 
FOREIGN PATENT DOCUMENTS 
1157695 
2008008357 Al 
2013132090 Al 
W02016/066862 
* 11/2001 
1/2008 
9/2013 
* 5/2016 
........... A61K 31/505 
OTHER PUBLICATIONS 
Martin et al., JBC, 2006; 281: 18933-18941 (Year: 2006).* 
Bergmann; EP15156995; Certified Priority Document of PCT/ 
EP2016/054106 (WO2016/066862): 31 pages total (Year: 2015). * 
Li et al., Nature, 2016; 533: 411; doi:10.1038/naturel7662 (Year: 
2016).* 
Pirollo et al., Cancer Res. 2008; 68(5): 1247-1250 (Year: 2008).* 
Winkler, Ther. Deliv. 2013; 4: 791-809 (Year: 2013).* 
Jafarlou et al., Journal of Biological Regulators & Homeostatic 
Agents, 2016: 30: 315-321 (Year: 2016).* 
Piche-Nicholas et al., MAbs. 2018; 10: 81-94. doi: 10.1080/19420862. 
2017.1389355 (Year: 2018).* 
Sarah Crunkhorn, Nature Reviews Drug Discovery; Published 
online Jun. 17, 2016; doi:10.1038/nrd.2016.121 (Year: 2016).* 
Armstrong, M. J., Parker, M. C., Ferris, C. F. & Leeman, S. E. 
Neurotensin stimulates [3H]oleic acid translocation across rat small 
intestine. Am J Physiol 251, G823-829 (1986). 
Birse, R. T. et al. High-fat-diet-induced obesity and heart dysfunc-
tion are regulated by the TOR pathway in Drosophila. Cell Metab 
12, 533-544 (2010). 
Boules, M. et al. A novel neurotensin peptide analog given extracrani-
ally decreases food intake and weight in rodents. Brain Res 865, 
35-44 (2000). 
Cooke, J. H. et al. Peripheral and central administration ofxenin and 
neurotensin suppress food intake in rodents. Obesity (Silver Spring) 
17, 1135-1143 (2009). 
Dobner, P.R., Fadel, J., Deitemeyer, N., Carraway, R. E. & Deutch, 
A. Y. Neurotensindeficient mice show altered responses to antipsychotic 
drugs. Proc Natl Acad Sci US A 98, 8048-8053 (2001). 
Drucker DJ. The role of gut hormones in glucose homeostasis. J 
Clin Invest 117:24-32, 2007. PMCID:1716213. 
Ernst, A., Hellmich, S. & Bergmann, A. Proneurotensin 1-117, a 
stable neurotensin precursor fragment identified in human circula-
tion. Peptides 27, 1787-1793 (2006). 
Evers, B. M. Neurotensin and growth of normal and neoplastic 
tissues. Peptides 27, 2424-2433 (2006). 
Fan, T. W., Lane, A. N., Higashi, R. M. & Yan, J. Stable isotope 
resolved metabolomics of lung cancer in a SCID mouse model. 
Metabolomics 7, 257-269 (2011). 
(Continued) 
Primary Examiner - Christina M Borgeest 
(74) Attorney, Agent, or Firm - Stites & Harbison 
PLLC; Mandy Wilson Decker 
(57) ABSTRACT 
The presently disclosed subject matter relates to a method 
for predicting increased risk of obesity on a non-obese 
subject. More particularly, the presently disclosed subject 
matter relates to a method of predicting increased risk of 
obesity in a non-obese subject by determining a level of 
neurotensin expression in a biological sample from the 
subject and comparing the level of neurotensin expression in 
the sample with a control level. The presently disclosed 
subject matter further relates to a method of preventing 
and/or treating obesity in a subject in need thereof by 
administering to the subject an effective amount of an agent 
that inhibits neurotensin. 
17 Claims, 19 Drawing Sheets 
Specification includes a Sequence Listing. 
US 10,473,670 B2 
Page 2 
(56) References Cited 
OTHER PUBLICATIONS 
Ferris, C. F., Hammer, R. A. & Leeman, S. E. Elevation of plasma 
neurotensin during lipid perfusion of rat small intestine. Peptides 2 
Suppl 2, 263-266 (1981). 
Gully, D., et al., Biochemical and pharmacological activities of SR 
142948A, a new potent neurotensin receptor antagonist. The Journal 
of Pharmacology and Experimental Therapeutics, 280:802-812 ( 1997). 
Gully, D., et al., Biochemican and pharmacological profild of a 
potent and selective nonpeptide antagonist of the neurotensin recep-
tor Proc. Natl. Acad. Sci. USA, vol. 90, pp. 65-69, (1993). 
Hardie, D. G. AMPK: positive and negative regulation, and its role 
in whole-body energy homeostasis. Curr Opin Cell Biol 33C, 1-7 
(2014). 
Kopelman, P. G. Obesity as a medical problem. Nature 404, 
635-643 (2000). 
Li, J. et al. Cyclic adenosine 5'-monophosphate-stimulatedneurotensin 
secretion is mediated through Rapl downstream of both Epac and 
protein kinase A signaling pathways. Mo! Endocrinol 21, 159-171 
(2007). 
Li, J. et al. mTORCl inhibition increases neurotensin secretion and 
gene expression through activation of the MEK/ERK/c-Jun pathway 
in the human endocrine cell line BON. Am J Physiol Cell Physiol 
301, C213-226 (2011). 
Li, J. et al. PI3K pll0alpha/Akt signaling negatively regulates 
secretion of the intestinal peptide neurotensin through interference 
of granule transport. Mo! Endocrinol 26, 1380-1393 (2012). 
Li, J. Chen, L.A., Townsend, C. M., Jr. & Evers, B. M. PKDl, 
PKD2, and their substrate Kidins220 regulate neurotensin secretion 
in the BON human endocrine cell line. J Biol Chem 283, 2614-2621 
(2008). 
Lim, C. T., Kola, B. & Korbonits, M. AMPK as a mediator of 
hormonal signalling. J Mo! Endocrinol 44, 87-97 (2010). 
Little TJ, Horowitz Mand Feinle-Bisset C. Modulation by high-fat 
diets of gastrointestinal function and hormones associated with the 
regulation of energy intake: implications for the pathophysiology of 
obesity. Am J Clin Nutr 86:531-41, 2007. 
Melander, 0. et al. Plasma proneurotensin and incidence of diabe-
tes, cardiovascular disease, breast cancer, and mortality. JAMA 308, 
1469-1475 (2012). 
Ogden, C. L., Yanovski, S. Z., Carroll, M. D. & Flegal, K. M. The 
epidemiology of obesity. Gastroenterology 132, 2087-2102 (2007). 
Piliponsky, A. M. et al. Neurotensin increases mortality and mast 
cells reduce neurotensin levels in a mouse model of sepsis. Nat Med 
14, 392-398 (2008). 
Sahu, A. Carraway, R. E. & Wang, Y. P. Evidence that neurotensin 
mediates the central effect of leptin on food intake in rat. Brain Res 
888, 343-347 (2001). 
Stenesen, D. et al. Adenosine nucleotide biosynthesis and AMPK 
regulate adult life span and mediate the longevity benefit of caloric 
restriction in flies. Cell Metab 17, 101-112 (2013). 
Vincent, J.P., Mazella, J. & Kitabgi, P. Neurotensin and neurotensin 
receptors. Trends Pharmacol Sci 20, 302-309 (1999). 
Service et al., Neurotensin in diabetes and obesity, 14 Regul. Pept. 
85 (1986). 
Williams et al., Reduced hypothalamic neurotensin concentrations 
in the genetically obese diabetic (ob/ob) mouse: possible relation-
ship to obesity, 40 Metabolism 1112 (1991). 
* cited by examiner 
U.S. Patent Nov. 12, 2019 Sheet 1 of 19 
a 
d 
60 
50 
:§ 40 
We<,k 1 4 7 10 13 16 19 22 
160 
HFD,ITT 
Min. l) 15 30 60 120 
o 1,0fil lo * ia o.a ....,. 
o .§ 0.6 
,c:: -
"' 0 .!.! ~ 0.4 
1-=- 0.2· 
::r: O NT +I+ NT ./. 
g 
60 
50 
§ 40· 
0 ....,......,.--,--,-....,..---,--,-..., 
Week1 4 7 10 13 16 19 22 
I.FD HFO 
Figures l A-H 
C 
US 10,473,670 B2 
NT+i+ 
ONT+!+ 
-NT-i- * 
'I' *t 
LFO HFD 
ONT+/+ 
-NT•i-
LFO HFO 
N1·1• 
e j. 
h 
OLFO 
-HFO 
U.S. Patent Nov. 12, 2019 Sheet 2 of 19 US 10,473,670 B2 
0.3 1.0 ·. 
0 o--
NT +j+ NT-1- NC HFD 
FIGURE2A 
Olive oil 
Control 30min 60min 
FIGURE 2B 
U.S. Patent Nov. 12, 2019 
Proximal 
intestine 
Sheet 3 of 19 
0.16 -
~ 0.12 
0 
E 
so.oa 
< 
0 
·~ 0.04 
0 
~ .,.. 
Plasma 
□ NT+t+ 
• NT•l-
0 ........,..__.....___ o.oo----
Saline 
p-AMPK 
AMPK 
{l-actin 
NT +t+ NT ·1-
FIGURE 2C 
Olive oil Olive oil + NT 
500 
1400 
.a 
t, 300 
I-
i 200 
.:: 
I 100 
s 
FIGURE 2D 
Proximal intestine 
NT "'1-t NT ·1• 
1234512 4 
FIGURE 2E 
Oh 1h 
US 10,473,670 B2 
* 
ti 
2h 3h 
0 Saline 
8 Olive oil 
■ Olive oil + NT 
NT•I+ NT..J• 
U.S. Patent Nov. 12, 2019 Sheet 4 of 19 
Olive oil 
Saline Olive oU +SR 49692 
1 23412341 2 4 
p«AMPK 
¥-f:Wf::m:;:p:~~:!fM::j:":~:}~: AMPK 
13-actin 
FIGURE 2F 
US 10,473,670 B2 
. '.b~ ()~ " ~ Oleate (mM) ·"b· ()~ ()• ()~ &.~~-&.c O• . (. M) ~- ~-~"--·"'•~,•.,J· 1-eate ·• m, . V v· V V 
p-AMPK 
AMPK 
p-actin -~--c•: 
FIGURE2G 
NT (pM) "~ 'l,~ ~~ 
Oleate (mM) - + + + + 
p-AMPK 
AMPK 
(3.-actin 
FIGURE 2H 
p-AMPK 
AMPK 
P-actin 
U.S. Patent Nov. 12, 2019 
siRNA NTC NTR1 ---
NT --++--++ 
Oleate - + - + - + - + 
.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.·.· 
p-AMPK I■ fit l)~f 111:1 
AMPK lff fii•lfi:fi:I;;:~:~ 
NTR 1 ■11■1■1■itittt Mt J/J 
l3-act1n ... !•o••i";;:;:: ...... ,
Sheet 5 of 19 US 10,473,670 B2 
siRNA NTC NTR3 
NT - - + + - - + + 
Oleate - + - + - + - + 
.:::;:;:;:;:;:::::::::::::::::::::::::::::::;:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
p-AM p K •Iht•t:Jlllllllld':>\~lIPM¥ 
AMPK 
NTRJ 
p-actin 
FIGURE2I 
NIT - - + 
AICAR - + + 
Oleate - + + + 
p-AMPK 
AMPK ·:iit::w:····iwiimr·•r·'··'l•••:'.:'.'.:·''J:•· 
FIGURE 2J 
BSA 
FlGURE2K 
U.S. Patent Nov. 12, 2019 Sheet 6 of 19 
- + - + - + Oleate 
p-AMPK 
........................................................ 
!lllilaig :M:;Mi AMPK 
............... . ................. . 
■''■ <H••· ■H■' LKB1 
:a,,,,,~,,•;1:;,1:1::: ca.MKK2 
r:.Ml:.:.iiit.R:.::a:::::a::::u:;:, P-act1n 
Flag-
Vector CaMKK2 
~ -++--++NT 
- + - + .. + ~ + Ofeate 
u,w,,,,,,,,,,,,,:;;:,:i!i@iii!i.:,_jjj,:ft p-AMPK 
:,:wiw::iitiWc::W::M:::WiW:WiW:::iw::i.ft:: AMPK 
FrGURE2L 
;;;;;;;;j;;;;j;;;;;;;;;;;j::•••• Flag-CaMKK2 
:NiijjiiiijiWOit_.,,., i3-act1 n 
FIGURE2M 
US 10,473,670 B2 
• + - + 
- ~ + + 
Flag-CaMKK2 
U.S. Patent Nov. 12, 2019 Sheet 7 of 19 US 10,473,670 B2 
a Control 
■ 
d Gr3<iC,w1118 Gr36C-w1118+HFO Gr36C-NT Gr36C-NT+HFO e 
f Control NT g Control Myo"•AMPK Myo"•AMPKRNAi 
i~,~j p-AMPK 
~---~~l AMPK 
1-liiiiii!IJ!!!Jjj[ ll-tubulin 
Figures 3A-G 
U.S. Patent Nov. 12, 2019 
d 
h 30 
§20 
lZ 
i 10 
0 
LFO HFO LFO HFO 
Lean Fat 
Sheet 8 of 19 US 10,473,670 B2 
O+.--........... -.......,..-........--,,...................., 
WeekO 5 10 15 20 25 
_Figures 4A-J 
U.S. Patent Nov. 12, 2019 Sheet 9 of 19 US 10,473,670 B2 
CJNr+I+ 6 
SJ)!)-
■ NT-i• 
l ~4oo 
,. f ~ g; i 300 
il'o 
~ ~ !_ 200 
is' Q> 
S ~ 100 
0 
b Ll'D H!'O 
d f'JNT';, t> []ITT+<• CJNT-:i" ONT''' 9 o.a ii ITT'" 1400 ■ NT"· 2$ ■ Nr" u. ■ NT"· 
f: 0.7 ' ?!_1200 1.0 x ., J! -20 
'5 O.i: t :g l 1000 " .!. t ~~ u; (LS t is J; 0.5 J .. • ~ ~ $00 --~ 15 Q:;. 
~is 0.4 "J:J ""<6 .r 0,6 
~~ O.J I~ 600 t~ 10 ~ !l.4 
I::' 0.2 
. ., e- ., g 2- U1 5 ~ ., 0.1 ◊,2 "' w l) ..: (I 0 
u=:n Hl'O LFO H!'O LFD HFD 
2-'lh Re&bng 
Exhmded Oata Fig, 4 
Figures SA-G 
U.S. Patent Nov. 12, 2019 Sheet 10 of 19 US 10,473,670 B2 
1 2 3 4 5 6 Human 1 2 3 4 5 6 Human 
HepG2 Mouse Mouse 
b 
Proximal intestine 
500bp-
NTR 
f3•actin 
fH.s741nt RlE-1 
Figures 6A-C 
U.S. Patent Nov. 12, 2019 Sheet 11 of 19 US 10,473,670 B2 
B-SA N•.T'. '' 
Figure 7A 
1200 *t *t 
-· iMiliMil e 800 ....... 
0, 
C -· C) 400 .... 
0 
,Qleate + + +· + 
NT (pM) - - 1x0 2 .. 0 4.0 
Figure 7B 
U.S. Patent Nov. 12, 2019 Sheet 12 of 19 US 10,473,670 B2 
siRNA NTC NTR1 NTR3 600 
500 
~400 
-~ 300 
$ 
BSA 
NT 
siRNA 
NT 
Oleate 
p-AMPK 
..E 200 
100 
0 
NTC NTR1 NTR3 
Figure 7C 
NT(pMJ 
Oleate 0.1 mM -· 
p-AMPK 
AMPK 
p.-actin 
+ + + + 
Figure 7D 
NTC NTR1 NTC NTR3 
--++--++ - - + + + + 
-+-+-+-+ -+-+-+-+ 
siRNA 
AMPK ••/>• ./ .... /••·••/> .. /<••••••••••·•·•••••·••·· 
p-AMPK 
AMPK 
NTR1 :•:• @rt *®iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii NTRJ 
Figure 7E 
U.S. Patent Nov. 12, 2019 
a 
b 
Control 
e Control 
f 
Control 
g 
Control 
Sheet 13 of 19 US 10,473,670 B2 
Gr36C-NT 
ts 
Myo -AMPK 
S106-AMPK 
5100-AMPK 
Figure 8 
<i 
Control NT 
i··~•:•:,m:::::::::::::::::::::::l p-AMPK 
1,~~f.f.Wjf~,1 AMPK 
t:.1: ....... Jlr •• -...1 !3-tubulin 
Myots -AMPKRNAi 
S106-AMPKRNAi 
·=,··=y,w==nm 
'·· 
;;~ 
I 
U.S. Patent 
a 
"' ,., 
"' "' "' "' ::, 
.t.l 
<( 
Nov. 12, 2019 Sheet 14 of 19 
100 
90-
80; 
70 
60 
50-
558.31140 
NT'· 
558.64478 
NT'' 
US 10,473,670 B2 
~ 40; ,. 
"' 30 £ 20-
10 
0; 
.....,..........,....,II I I ' 1l,....,..~
5
~5S..,.NT .... 
9
.,..~?_
5
-
2
....,,....l1L.,~11.~l, ... 
558.0 568.5 569.0 559.5 
mlz 
b 100 
60 
50 ~ 
! 40;! 
i 30i 
20 j 
10-
520,94 
Y12'' 
484.05: 
Y11''. 
I 
.... , 
o;J;,,,,:,,~W-flll!IIII 
300 
643.64 
Y10'' 
725.23 
Y11'' 
771.74 
Y 12''--H.,O 
C 
NT 
NT{1-13l o:.oncentratlon ln S2 cell culture medium I 67 x 1-0·" g/m! 
NT(1-13lin control fly gut i N.O, 
A,terage amount of NT(1-13i in Gr3SC--NT lly gut i 3.1 x HJ·" g,'gut 
E-..tended Oata Fig. 8 
Figure 9 
:Figure JOA 
0 Control 
Ill Indicated dsRNA 
Im GFPdsRNA 500 
~ 400 
~ 300 Cl 
::: 
j:'200 
z 100 
o~----
ub-Gal4 ub--Gal4-NT 
U.S. Patent Nov. 12, 2019 
Vector NT 
Control 
Sheet 15 of 19 US 10,473,670 B2 
Figure lOB 
< 1.2 
~ 1.0 
e- o.a 
11.t t 0.6 
~ ,! 0.4 
t 0.2 
.,.,.,.,.,.,. 
a: 0 .J.-J....---1----JI 
Figure lOC 
TK-NT 
Figure lOD 
Control Capa GFP 
dsRNA dsRNA 
TK-NT + Myo1A .. 
CG9918RNAil'l5:l8' 
U.S. Patent Nov. 12, 2019 Sheet 16 of 19 US 10,473,670 B2 
Mouse NTR1 SGNSSESn.Effram.DVNTDrISKVLVTA~~ 
+GNS + l? L.+ +VTVY +F+GVGN T +++s++ 
Fly CG9918 AGNMSHDWPPRDFLAI------VIPVT'iNYSI.IFI~IS'l'CIV~---
Identities: 32.1 % ~LI.!~YNF~~FI.RDACT'lATALNV 
Positives: 50,5% +Y+L SIA+SD I.+LL +PE+ ++rw +1?+ ro+ CG L + AT L + 
A'l'NYYLFSLAISD~-SYIWSKYl?YVFGEYICIGRGI.T.J\ETSANATVLTI 
ASLSVERYLAICHP~RTKKFISAIWLASALLA~ADGQffl? 
+ +VERY+AICHPF + + SR + I +w+ + + A+P G+++ S G 
TAF'T"JERYIAICHF~IVLVWDmlVTAI~IEHY.S--GVEQ 
GGLVCTPTVDTATVKV'ITQVNT'.EMSFLFE'MLIISILNTVIANKL--~AEglR--
G+V 'V.K Q++TF+ FL PM II -+L +I L + +V A R 
CGIV------RVIVRHSFQI.STFIFFLAPMSI.!LVI.YLI.IG\JHLYRSTI.VEGP~ 
---------------~s----------1.EHST.F'NMSIEPGRV'Q--ALRHGVL 
GT+N +S +s GR.+ R+ 
QL!WVFSOTILYRYOOSGT.AMS~~LSSVRGRLNHYGTRRVLR 
vmAW::tAFVVCWLP~I.SOEQWf'l'FLFD~----TNALFYVSSAI 
+L AW+ F +cW l?+R +ru:..+ Y L D + + Y + + L+Y+S+ I 
MLVAVWCFFLOllAPF.m\QRLIAJ:nl?ARGAK--~YnSTCI 
NFILYNL~TL 384 
NP+LYN++.S FR+ F + L 
Nl?LLYNIM!.:l~VL 362 
Figure lOE 
U.S. Patent 
a 
12 
e-i 10 
(.) O> 
- I:: ,S-Sl 8· 
m-
i:; !8 6 
<11 <Ii -~ 4 :,. ; 
,:i-
0 ~ 2 
(ti~ 
0 ·Nr,..,:.:· .. 
l!'O Hfl> 
Nov. 12, 2019 Sheet 17 of 19 
b 
Ei 
(.) O> 
-i:: 
,S-Sl 
m-
i:: ro 
<11 <Ii -~ :,.; 
,:i-
0~ 
(ti~ 
H&E 
~ b 10 ''j 8 6 ~ 0.8 e o.6 r 4 
in M ➔ 
2 
§ ;~ I 
0.2, 
0 ... ..... ... 0 ,;... ..... . .. 
NT+!+ Nr·1• NT+/+ NT.f. 
e 
400 
I 380 
;l:; 360 
,!? 
~ 340 
"' .:! 320 
$ 
Figures llA-F 
fil 0.5 
f 
O-'-<---~----- o;...,...-,,_ __ ..,...._, 
Min. 0 15 30 60 120 Min. 0 
Figures 12A-C 
FIGURE 13A 
US 10,473,670 B2 
C 
40 
~ 35 
E 30 <.> 
~ 25 
Q> 20 
I: 15 !!! 
10 m 
5 
0 .NT +i+ .. NT;; 
25 
Fa&tad Refod 
U.S. Patent Nov. 12, 2019 Sheet 18 of 19 
0 
Olive oil .. + + ,. + + 
SR 48692 .. • + ,. • + 
50 -0, 
- 40 
~ 
OO 30 
.?:-
= 20 
~ 10 
NT+1+ NT•i• 
FIGURE 13B 
-· Vehicle 
""'"" SR 48692 
0 +---.---.---.---.---.--.-...... 
Week O 2 4 6 8 10 12 14 
FIGURE 13C 
25 
e 
i-;-20 
t: th ·- ::, 8 ~15 
..... loo. 
~t10 
,::.:, Ql :-
~ 5 
US 10,473,670 B2 
·•·•·•·• Vehicle 
-w SR 48692 
0------------
WeekO 2 4 e a 10 12 14 
FIGURE 13D 
U.S. Patent Nov. 12, 2019 Sheet 19 of 19 US 10,473,670 B2 
A B 
Mice 
A 
2500 
:::::- :woo 
.€_ 1500 
&'. 
;: 1000 
BON C 
;a: 500 +·1 o,,J.,.,l--i.._.._ 
1200 
-1000 
s soo 
1f 600 
'i= 400 
z 200· 
0 
OA{mM} • OA (mM) • 0,1 0,5 1.0 0.1 0.5 HJ 
p AMPKMMMM❖••--- p.AMPK 
AMPK 
P·ACC 
ACC 
Figures 14A-C 
Figures lSA-B 
p-ACC 
ACC 
B 
5 
0hffAR1 
llhFFAR4 
B . . + + cc 
AICAR{mMl , -0,2!> il.5 1.-0 .... ~ .... :+ .... · ...... + ... AlCAR 
!)-SGK1 ,:;#.#, •• #@>,·@:@:@:;::::·;::::· ---µ-S6K1 
~~1';1 i±><te>.«:.: .. >.: ... •··.:················ ;.:_,··•UK1 
P-eRKi/2 :·:::::: :·::::::·r••@Iaet·;wtjl•eRKl/2 
ERK g:i■::■:r1t· ■ilil!■ ERK 
~actin •:•:•:•:•.· •»:-» ····~· -~:• ::i#:#;~;q;;~;#;#;/~:: ~sctffi 
Figures 16A-D 
US 10,473,670 B2 
1 
METHOD OF PREDICTING OBESITY 
COMPRISING MEASURING NEUROTENSIN 
RELATED APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application Ser. No. 62/299,688, filed Feb. 25, 2016, the 
entire disclosure of which is incorporated herein by this 
reference. 
STATEMENT OF GOVERNMENT INTEREST 
This invention was made with U.S. Government support 
under contract no. R37 AG10885, ROI DK048498, ROI 
GM079684, U24 DK097215, ROI ES022191, POI 
CA163223, P20 GM103527, ROI HL120507, ROI 
HL073085, and P20 GM103527 awarded by the National 
Institutes of Health. The U.S. Government has certain rights 
in the invention. 
TECHNICAL FIELD 
The presently disclosed subject matter relates to a method 
for predicting increased risk of obesity on a non-obese 
subject. More particularly, the presently disclosed subject 
matter relates to a method of predicting increased risk of 
obesity in a non-obese subject by determining a level of 
neurotensin expression in a biological sample from the 
subject and comparing the level of neurotensin expression in 
the sample with a control level. 
BACKGROUND 
Obesity and its associated comorbid conditions are among 
the most prevalent and challenging conditions confronting 
the medical profession in the 21st century. Estimates by the 
World Health Organization indicate that over 1.7 billion 
people worldwide are overweight (BMfa:25) or obese 
(BMfa:30) with over 2.5 million deaths annually attributable 
2 
This summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
summary is merely exemplary of the numerous and varied 
5 embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 
embodiment can typically exist with or without the fea-
ture(s) mentioned; likewise, those features can be applied to 
other embodiments of the presently-disclosed subject mat-
IO ter, whether listed in this summary or not. To avoid exces-
sive repetition, this summary does not list or suggest all 
possible combinations of such features. 
In some embodiments, the presently-disclosed subject 
15 
matter includes a method of predicting increased risk of 
obesity in a non-obese subject, comprising contacting a 
biological sample from the subject with a probe for neuro-
tensin to determine the amount of neurotensin in the bio-
logical sample; comparing the amount of neurotensin to a 
20 control level; and determining that the subject has an 
increased risk of obesity if there is a measurable difference 
in the amount of neurotensin in the sample as compared to 
control level, wherein an increased neurotensin level is 
predictive of an increased risk of becoming obese. In one 
25 embodiment, the method further comprises measuring the 
phosphorylation level of AMPK in the biological sample; 
and comparing the measured phosphorylation level to a 
control level, wherein a decreased level of phosphorylation 
level is predictive for an increased risk of becoming obese. 
30 In another embodiment, the biological sample comprises 
blood, plasma, serum, plasma, and tissue. In a further 
embodiment, the risk of becoming obese is independent of 
baseline body mass index. 
In some embodiments, the neurotensin is pro-neurotensin, 
35 which may be detected by a technique comprising RNA 
measuring assays and protein measuring assays. One suit-
able RNA measuring assay comprises real time reverse 
transcription polymerase chain reaction. The obesity may 
include, but is not limited to, prevalent obesity, prevalent 
to obesity. In the U.S., adult obesity rates rose from 14% in 
1978 to over 30% in 2000 with over 50% of Americans 
projected to be obese in 2030. Common comorbidities of 
over-nutrition and obesity include insulin resistance and the 
development of hepatic steatosis (i.e., nonalcoholic fatty 
liver disease, which is noted in about 75% of obese patients). 
However, the mechanisms responsible for obesity and other 
metabolic sequelae associated with overconsumption of 45 
dietary fats are poorly understood. 
40 abdominal obesity, and/or new-onset obesity. Additionally 
or alternatively, the method further comprises administering 
to the non-obese subject preventative treatment for obesity. 
In one embodiment, the preventative treatment includes 
administration of a neurotensin inhibitor. 
In some embodiments, the presently-disclosed subject 
matter includes a method of detecting reduced intestinal fat 
absorption in a subject, comprising contacting a biological 
sample from the subject with a probe for neurotensin to 
determine the amount of neurotensin in the biological 
The small intestine plays a central role in the control of 
energy homeostasis through the digestion, absorption and 
assimilation of ingested nutrients. Food ingestion is associ-
ated with the increased secretion of multiple gut peptides, 
produced in specialized enteroendocrine cells scattered 
along the length of the small bowel, that act on distant target 
sites ( e.g., liver, muscle and adipose tissue) to promote the 
efficient uptake and storage of energy, and the regulation of 
lipid and glucose homeostasis. While GI hormones can 
regulate energy balance in a number of ways, the role that 
gut hormones play in obesity and metabolic disorders is 
poorly understood. 
Accordingly, methods for predicting increased risk of 
obesity in non-obese subjects is desirable. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
50 sample; comparing the amount of neurotensin to control 
level; and determining that the subject has reduced intestinal 
fat absorption if there is a measurable difference in the 
amount of neurotensin in the sample as compared to control 
level, wherein a decreased neurotensin level is indicative of 
55 reduced intestinal fat absorption. In one embodiment, the 
method further comprises measuring the phosphorylation 
level of AMPK in the biological sample; and comparing the 
measured phosphorylation level to a control level, wherein 
an elevated phosphorylation level is indicative of reduced 
60 intestinal fat absorption. 
In some embodiments, the presently-disclosed subject 
matter includes a method of preventing and/or treating 
obesity in a subject in need thereof, comprising administer-
ing to the subject an effective amount of an agent that 
65 inhibits neurotensin. In one embodiment, the method further 
comprises administering a pharmaceutically acceptable car-
rier. In another embodiment, the agent includes, but is not 
US 10,473,670 B2 
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limited to, a neurotensin inhibitor, a neurotensin receptor 
antagonist, a small molecule, a peptide, and/or siRNA. 
Further features and advantages of the presently-disclosed 
subject matter will become evident to those of ordinary skill 
4 
analyzed by western blotting (left panel). Densitometric 
quantification of p-AMPK was normalized by total AMPK 
and the graph demonstrates the fold change of p-AMPK vs. 
in the art after a study of the description, figures, and 5 
non-limiting examples in this document. 
saline (right panel, n=S). * p<0.05 vs. saline; t p<0.05 vs. 
olive oil alone. G. Human small intestinal cells (FHs74Int) 
(left panel) and RIE-1 cells (right panel) were treated with 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIGS. lA-H includes images and graphs showing protec-
tive effects of neurotensin (NT)-deficiency on obesity and 
comorbid conditions. A. Image (upper panel) and graph 
(lower panel) comparing body weight of male Nr1+ and 
NT-1- mice fed a high-fat diet (HFD). B. Image (upper 
panel) and graph (lower panel) comparing body weight of 
female Nr1+ and NT-1- mice fed a high-fat diet (HFD). 
Representative images taken at 24 wks. Body weight (BW) 
was measured weekly for 22 wks; BW slopes were com-
pared: * p<0.05 NT+1+ vs. NT-1- mice. Male NT+1+=l8 and 
NT-1-=15 mice; 54.6 g vs. 42.9 g; female Nr1+=15 and 
NT-1-=12 mice; 49.2 g vs. 35.9 g at the end time point. C. 
Plasma glucose (upper panel) and insulin (lower panel) 
levels quantified in 24 h-fasted male mice maintained on a 
LFD or HFD for 24 wks (n=S-10); * p<0.05 vs. LFD in 
NT+/+ and NT_;_ mice, respectively; t p<0.05 vs. HFD in 
NT+!+ mice. D. Blood glucose (BG) during insulin tolerance 
test (ITT) (left panel) and glucose tolerance test (GTT) (right 
panel) in 6 h-fasted male mice fed a HFD for 24 wks 
(n=3); * p<0.05 vs. NT_;_ mice. E. Gross, H&E and oil red 
0 (ORO) imaging of livers of male mice fed a HFD for 24 
wks (n=5). F. Hepatic triglyceride (TG) and cholesterol were 
analyzed by liquid chromatography-mass spectrometry (LC-
MS) in 24 h-fasted male mice fed a HFD for 24 wks 
(n=3). * p<0.05 vs. Nr1+ mice. G. H&E staining of epi-
didymal fat from male NT+/+ and NT-1- mice fed a LFD or 
HFD for 24 wks. H. Quantitative analysis of adipocyte area 
(n=6). * p<0.05 vs. LFD in Nr1+ and NT_;_ mice, respec-
tively; t p<0.05 vs. LFD in Nr1+ mice; p<0.05 vs. HFD in 
NT+!+ mice. All data are mean+/-SD. 
the indicated concentrations of oleate for 1 h and lysates 
were analyzed by western blotting. H. FHs 74 Int cells were 
pre-treated with or without NT at different dose as indicated 
10 for 30 min followed by combined treatment with oleate (0.1 
mM) for 1 hand western blotting of cell extracts (left panel); 
densitometric analysis of p-AMPK is from 3 separate 
experiments and normalized to total AMPK; graph demon-
strates the fold change of p-AMPK vs. BSA (right panel). * 
15 p<0.05 vs. BSA; t p<0.05 vs. oleate alone. I. FHs74Int cells 
transfected with NTRl (100 nM), NTR3 (20 nM), and 
control (100 and 20 nM, respectively) for 3 d were treated 
with oleate (0.1 mM) or BSA in the presence or absence of 
NT (2 µM) for 1 hand cell extracts were analyzed as in (g). 
20 J. FHs 74 Int cells were treated with or without NT (2 µM) 
for 30 min followed by AICAR (1 mM) for 2 h and oleate 
(0.1 mM) for 1 hand analyzed by western blot (left panel); 
p-AMPK levels were determined as in (h) from 3 separate 
experiments (right panel). * p<0.05 vs. BSA; t p<0.05 vs. 
25 oleate alone; t p<0.05 vs. oleate+AICAR. K. FHs74Int cells 
were treated with NT (2 µM) for 30 min followed by 
addition of AICAR (1 mM) for another 3 h; cells were then 
incubated with BSA or BODIPY® FL C16 (C16) for 15 min 
and images taken by confocal microscopy. L. FHs74Int cells 
30 transfected with LKBl, CaMKK2 and control (all 40 nM) 
siRNAs for 3 d were treated with oleate (0.1 mM) or BSA 
in the presence or absence of NT (2 µM) for 1 h and cell 
extracts were analyzed as in (g). M. FHs74Int cells trans-
fected with Flag-CaMKK2 and control vector for 48 h were 
35 treated with or without oleate (0.1 mM) or NT (2 µM) and 
analyzed by western blotting. p-AMPK levels were deter-
mined as in (g) from 3 separate experiments (right panel). * 
p<0.05 vs. BSA in vector- and CaMKK2-transfected cells, 
respectively; t p<0.05 vs. BSA in vector-transfected cells; t 
40 p<0.05 vs. oleate in vector-transfected cells; # p<0.05 vs. FIGS. 2A-M includes images and graphs illustrating NT 
deficiency reduces intestinal lipid absorption. A. (left panel) 
Fecal triglyceride (TG) was analyzed in male mice fed a 
high-fat diet (HFD) for 24 wks (n=3); * p=0.05 vs Nr1+ 
mice; (right panel) Fecal weight was measured in male 
Nr1+ and NT-1- mice (n=7-9) fed either normal chow (NC) 45 
or HFD for 24 wks; there was no significant difference 
between genotypes. B. Oil red O (ORO) staining of proxi-
mal intestines from male mice (6-mo-old) under normal 
chow fed with or without olive oil by gavage after overnight 
fasting (n=3). C. Levels of 13C18-oleic acid (OA) in male 
mice (5-mo-old) under normal chow fed with 13C18-OA 
mixed in olive oil by gavage after an overnight fast was 
analyzed by nanospray FT-MS (n=3-4). Left panel, * p<0.05 
BSA in vector-transfected cells; & p<0.05 vs. NT alone in 
vector-transfected cells; § p<0.05 vs. oleate+NT in vector-
transfected cells. All data are mean+/-SD. Experiments in 
vitro were at least repeated three times. 
FIGS. 3A-G includes images and graphs showing NT 
suppresses adenosine monophosphate-activated protein 
kinase (AMPK) activation and promotes lipid accumulation 
in Drosophila. A. Midguts from 7 d adults expressing 
Gr36C-Gal4 (control, 100%, n=5)) or Gr36C-NT (93%, 
50 n=15) were stained with Nile Red. B. Oenocytes on the basal 
surface of the lateral epidermis of 3rd instar larvae express-
ing Gr36C-Gal4 (control, 100%, n=15) or Gr36C-NT (93%, 
n=15) were stained with Oil Red O (ORO) to monitor lipid 
accumulation. C. Fat bodies attached to the salivary gland 
55 from the 3rd instar larvae expressing Gr36C-Gal4 (100%, 
n=S) or Gr36C-NT (100%, n=S) were photographed using 
DIC microscopy. D. Flies with the indicated genotypes were 
treated with either normal food (NF) or high-fat diet (HFD), 
and guts were stained with Nile Red to examine the accu-
vs. NT+/+ mice. Right panel, *t p<0.05 vs. 0 h in NT+/+ and 
NT_;_ mice, respectively; p<0.05 vs. 2 h and 3 h in NT+/+ 
mice. D. ORO staining of proximal intestines from male 
mice (5-mo-old) following gavage with or without olive oil 
plus NT after an overnight fast (left panel); TG was quan-
tified (right panel) (n=5). * p<0.05 vs. Saline in Nr1+ and 
NT_;_ mice, respectively; t p<0.05 vs. olive oil in NT_;_ 
mice; t p<0.05 vs. olive oil in NT+/+ mice. E. Western blot 
analysis of proximal intestinal mucosa from 24 h-fasted 
male mice (12-mo-old) maintained on a normal chow (left 
panel). Densitometric quantification of p-AMPK was nor-
malized to total AMPK and is presented as fold change vs. 65 
p-AMPK in Nr1+ (right panel, n=9). * p<0.05 vs. Nr1+. F. 
Protein extracts from mucosa! scrapings of samples were 
60 mulation of lipids (arrows). Shown here are representative 
images from each group (n=5). E. NT was expressed by 
voila-Gal4 and adult flies fed either NF or HFD were 
subjected for triglyceride (TG) analysis and normalized with 
protein concentration38 (n=25 per group). * p<0.05 vs. NF in 
control- and NT-expressing flies, respectively; t p<0.05 vs. 
NF in control-expressing flies; t p<0.05 vs. HFD in control-
expressing flies. F. Western blotting shown to monitor the 
US 10,473,670 B2 
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levels of AMPK in adult midgut same as (A). G. MyolA-
Gal4 combined with tub-Ga!S0's (Myo's) does not express 
Gal4 at 20° C. permissive temperature. Shown in the left 
panel is the midgut from a 7 d adult bearing Myo'5 -AMPK 
raised at 20° C., stained with Nile Red, and used as a control 5 
(100%, n=15). Midguts expressing AMPK (middle panel, 
100%, n=15) or AMPK RNAi25931 (right panel, 87%, n=15) 
from 7 d adults at 29° C. were stained with Nile Red. The 
levels of AMPK were monitored by western blot. 
6 
colon as well as human duodenum (duo) and colon. Proteins 
from HepG2 (a human hepatocellular carcinoma cell line) 
and Caco-2 (a human colon cancer cell line) cells stably 
expressing NTRl, NTR3, or control (NTC) shRNA were 
used as positive and negative controls. B. IHC was per-
formed on mouse proximal intestines for NTRl and NTR3 
expression. C. Total RNA was isolated from human 
(FHs74Int) and rat (RIE-1) small intestinal epithelial cells 
and RT-PCR performed using specific primers targeting 
FIGS. 4A-J shows NT deficiency inhibits high-fat diet 
(HFD)-induced obesity. A. Epididymal fat pad (arrows) 
from male mice (5-mo-old) maintained on a normal chow 
before dissection. B. Epididymal fat pad from male mice 
(5-mo-old) maintained on a normal chow after dissection. C. 
Retroperitoneal fat pad from male mice (5-mo-old) main-
tained on a normal chow (arrows). D. Representative epi-
didymal (arrows) fat pads of male mice fed a HFD for 24 
wks. E. Representative retroperitoneal fat pads of male mice 
fed a HFD for 24 wks. F. Representative pericardia! fat pads 
of male mice fed a HFD for 24 wks. G. Weekly body weight 
changes of male and female mice placed on a LFD for 25 
wks Male NT+!+ n=13 NT_;_ n=13 mice· female NT+/+ 
n=12, NT-1- n=14 mice'. There is no statisti;al significance 
between NT+!+ and NT_;_ in both male and female mice. H. 
Fat composition was measured by EchoMRI in male mice 
fed LFD or HFD for 24 wks (n=5). *p<0.05 vs. LFD fat; 
tp<0.05 vs. Nr1+ LFD fat; t p<0.05 vs. Nr1+ HFD fat; 
#p<0.05 vs. Nr1+ HFD lean. I. H&E staining of epididymal 
10 human or rat NTRl, 2 and 3. 
fat pad from male mice as in FIG. lg; arrows showing the 
inflammatory cells. J. F4/80 IHC staining of epididymal fat 
pad from HFD-fed mice as in FIG. lg; arrows showing 
F4/80+ cells. All data are mean+/-SD. 
FIGS. SA-G includes graphs showing NT deficiency does 
not alter food intake, energy intake, energy expenditure, 
locomotor activity and resting respiratory exchange ratio 
(RER). A. Graphs showing cumulative food intake of male 
(left panel) and female (right panel) mice fed LFD and HFD. 
Analysis of cumulative food intake for 22 wks did not show 
FIGS. 7A-E shows NT promotes intestinal cell lipid 
absorption or accumulation. A. RIE-1 cells were pre-treated 
with BSA or NT (2 µM) for 30 min and BSA-conjugated 
BODIPY® FL C16 was added and incubated for 15 min 
15 followed by confocal microscopic analysis. B. RIE-1 cells 
were pre-treated with or without NT at different concentra-
tions for 30 min followed by the addition of BSA-conju-
gated oleate (0.1 mM) and further incubation overnight. 
Cells were collected, lysed and Triglyceride (TG) was 
20 measured (n=3). * p<0.05 vs. BSA only (-); t p<0.05 vs. 
oleate only. C. RIE-1 cells transfected with non-targeting 
control (NTC) siRNA or siRNA directed to either NTRl or 
NTR3 for 72 h were treated with or without NT (2 µM) for 
30 min followed by incubation of BSA-conjugated 
25 BODIPY® FL C16 (C16) for 15 min. Images were taken by 
confocal microscopy and green intensity quantified as 
described in the methods section. n=30 cells; * p<0.05 vs. 
cl6 in NTC siRNA; t p<0.05 vs. cl6 plus NT in NTC 
siRNA. D. RIE-1 cells were pre-treated with or without NT 
30 for 30 min followed by combined treatment by BSA or 
BSA-conjugated oleate (0.1 mM) for 1 h and western blot 
performed. E. RIE-1 cells were transfected with siRNA 
directed to either NTC, NTRl (100 nM) (left panel) or 
NTR3 (20 nM) (right panel) for 3 d, treated with NT (2 µM) 
35 and oleate (0.1 mM) as in (d) and analyzed by western 
blotting. All data are mean+/-SD. Experiments were 
repeated at least three times. 
FIGS. SA-G includes images illustrating NT regulates 
lipid droplet accumulation and AMPK activation in Droso-
40 phila midgut, fat body, and oenocytes. A. Midgut from a 7 
d adult expressing NT by Gr36C-Gal4 was stained for NT 
and Prospero (Pros). Inset shows NT co localization with 
Pros. B. Characterization of the Gr36C-Gal4 expression in 
enteroendocrine cells. An adult midgut expressing GFP 
a significant difference except in female mice fed HFD 
(p=0.04). B. Graphs showing weekly food intake of male 
mice on LFD (left panel) and HFD (right panel). C. Graphs 
showing weekly food intake of female mice on LFD (left 
panel) and HFD (right panel). For weekly food intake, there 
was no significant difference between genotypes in male 
mice on both diets (B) and female mice fed LFD (C, left 
panel); food intake on week 9 in female mice fed HFD 
reached significance between genotypes (C, right panel). For 
A-C, food intake was measured weekly for NT+/+ and NT_;_ 
male (LFD n=3 and HFD n=4) and female (LFD n=3 and 
HFD n=4) mice. D. Energy expenditure of male mice on 50 
LFD and HFD diets for 24 weeks, presented by the average 
kcal/h in 24 h and in resting period. E. Locomotor activity 
45 under the control of Gr36C-Gal4 was collected from 7 d 
adult flies raised at 25° C. normal temperature and stained 
for GFP and Pros. Inset in the merged channel shows high 
magnification image indicating colocalization of GFP with 
Pros. C. Expression of NT promotes the accumulation of 
lipid droplets. Left panel, a control midgut from 3rd instar 
larvae expressing Gr36C-Gal4 alone was stained with Nile 
Red to label the lipid droplets (100%, n=7). Right panel, a 
midgut expressing NT by Gr36C-Gal4 was stained with Nile 
Red (93%, n=15). D. The entire gastrointestinal tracts from 
larvae as in ( c) bearing the indicated genotypes were lysed 
and subjected to western blot analysis with the indicated 
of male mice on LFD and HFD diets for 24 weeks, which 
represents counts of beam breaks in a 30 min-period. F. 
Energy intake of male mice on LFD and HFD diets for 24 55 
weeks, which represents the food intake in kcal for 24 h. G. 
Resting RER of male mice on LFD and HFD diets for 24 
weeks. In D-G, male mice on LFD and HFD diets for 24 wks 
were placed in individual cages and indirect calorimetric 
analysis performed (n=l0).ANCOVAtest, * p<0.05 vs. LFD 60 
in Nr1+ mice; t p<0.05 vs. LFD in NT-1- mice. All data are 
mean+/-SD. 
antibodies. E. Left panel, a midgut from 3rd instar larva 
bearing Myo's -AMPK raised at 20° C. stained with Nile Red 
as control. Myo'5 -AMPKRNAi25931 at 20° C. permissive 
temperature showed similar Nile Red staining to that of 
Myo'5 -AMPK at 20° C. Middle and right panels, midguts 
expressing AMPK or AMPKRNAi25931 under the control of 
Myo's were collected from 3rd instar larvae and stained with 
Nile Red. Fly embryos bearing the indicated genotypes were 
FIGS. 6A-C includes images and graphs illustrating Neu-
rotensin receptor (NTR) expression in small bowel. A. 
Expression ofNTRl (left panel) and NTR3 (right panel) was 
analyzed by western blot from mucosa scraped from mouse 
proximal (pro), middle (mid), distal (dis) small bowel and 
65 raised at 20° C. until 96 h AEL and then switched to 29° C. 
nonpermissive temperature to induce Gal4 expression. The 
overexpression and RNAi efficiency of AMPK were moni-
US 10,473,670 B2 
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tared with an anti-AMPK antibody from Cell Signaling 
Technology by western blot analysis (not shown). Shown 
here are representative images (n=7 for each group). F. The 
RU486-dependent S106-Gal4 driver was used to overex-
press or inhibit AMPK expression to examine lipid droplet 5 
accumulation in fat bodies in 3rd instar larvae. Representa-
tive DIC micrographs ofS106-Gal4-AMPK without RU486 
(left panel, 100%, n=l0). Similar results were obtained for 
S106-Gal4-AMPKRNAi25931 without RU486), S106-Gal4-
AMPK with RU486 (200 µM in food, middle panel, 80%, 10 
n=l0), and S106-Gal4-AMPKRNAi25931 with RU486 (right 
panel, 90%, n=l0). To achieve precise comparison, fat 
bodies attached to the salivary glands from different geno-
types were analyzed. G. As in (E), except that oenocytes 
were stained with Oil Red Oto examine lipid accumulation, 15 
genotypes and RU486 treatment are indicated. Compare 
middle panel (80%, n=l0) and right panel (90%, n=l0) to 
the left panel of control (100%, n=l0). 
FIGS. 9A-C. LC-MS/MS analysis of the processed NT 
peptide. A. The mass spectrum of the triply charged NT 20 
(NT3+) peptide eluted at 18.96 min in conditioned medium 
of S2 cells expressing full-length human NT precursor. The 
labeled three peaks are the isotopic envelope of NT3+ with 
a mass accuracy less than 2 ppm from the theoretical m/z 
value of 585.31050. B. The tandem mass spectrum of the 25 
triply charged NT3+ peptide. The m/z values of major 
fragment ions are designated, confirming the peptide as 
biologically active 13-amino acid NT. C. The amount of NT 
in S2 medium and fly GI tracts (350 guts collected for each 
sample) from adult Gr36C-NT flies was quantified (N.D., 30 
not detected). 
FIGS. lOA-E shows CG9918 (mouse NTRl analog) 
RNAi blocks the NT-mediated decrease of p-AMPK levels 
in Drosophila S2 cells. A. S2 cells were transfected with 
ub-Gal4 plus UAST-NT (ub-Gal4-NT) or control (ub-Gal4) 35 
vector and treated with the indicated dsRNA to knockdown 
individual receptors. Cell lysates were subjected to western 
blot with the indicated antibodies to examine the activation 
8 
NO: 1) and Drosophila CG9918 (SEQ ID NO: 2), identities 
and conserved residues ( +) are indicated. All data are 
mean+/-SD. Experiments in vitro were repeated at least 
three times. 
FIGS. llA-F show graphs illustrating that NT deficiency 
does not affect body length or small intestine morphology. A. 
Body length of both NT+!+ and NT_;_ mice was measured 
and did not differ significantly between genotypes for either 
male or female mice (n=l2-13/genotype/sex). B. Average 
weight of the small intestine for male NT+/+ and NT_;_ mice 
(n=7/genotype). C. Average length of the small intestine for 
male Nr1+ and NT_;_ mice (n=7/genotype). D. H&E stain-
ing of proximal intestinal samples from male NT+/+ and 
NT-1- mice (bar=50 µm). E. Villus height measurements 
from proximal intestinal samples of male NT+/+ and NT_;_ 
mice, which show no significant differences between geno-
types. F. Crypt number measurements from proximal intes-
tinal samples of male NT+/+ and NT_;_ mice, which show no 
significant differences between genotypes. Mice (7 months) 
for all experiments were maintained on standard chow after 
weaning and all data are plotted as mean+/-SD. 
FIGS. 12A-C show graphs and images illustrating that NT 
deficiency improves insulin/Akt signaling and reduces adi-
pocyte inflammation. A. NT+/+ and NT_;_ mice fed LFD or 
HFD for 22 wks after weaning were fasted overnight. Saline 
or insulin (5 units) was injected into the IVC. Five min after 
the injection, liver tissues were collected and protein extracts 
analyzed by western blot. A representative result is shown 
from 3 separate experiments. B. Male NT+!+ and NT-1- mice 
(7-mo-old) fed standard chow after weaning were fasted 
overnight followed by glucose (2 mg/kg) administration by 
gavage (n=5/genotype). Blood samples were collected both 
prior to and at the indicated times after glucose administra-
tion for measurement of plasma insulin (left panel) and 
glucose (right panel) levels. No statistically significant dif-
ferences in either insulin or glucose levels were apparent 
between genotypes. C. Male NT+!+ and NT_;_ mice (12-mo-
old) fed standard diet after weaning were fasted for 16 h or of AMPK (left panel). The efficiency of RNAi knockdown 
was monitored by real time-PCR (middle panel). * p<0.05 
vs. control dsRNA. Medium from cells expressing either 
ub-Gal4 alone or ub-Gal4-NT was collected to examine the 
levels of NT by NT EIA (right panel); * p<0.05 vs. ub-Gal4. 
40 fasted for 16 hand refeed for 4 h (n=3/genotype ). Blood was 
collected from IVC and plasma used to measure insulin. * 
p<0.05 vs. fasted NT+/+ mice. 
B. S2 cells were treated with the indicated concentrations of 
NT peptide for 1 h and AMPK activation was monitored as 
FIGS. 13A-D show graphs and images illustrating that 
NT promotes intestinal cell lipid absorption or accumula-
45 tion, while NT deficiency reduces intestinal lipid absorption 
A. Proximal intestines from mice given saline, olive oil, or 
olive oil+SR 48692 were collected and TG levels quantified 
as described above (n=8). Graph presents the fold change vs. 
in (a). NT treatment (0.2, 0.5 µM) decreased p-AMPK to 
levels similar to those observed in ub-Gal4-NT transfected 
cells where NT levels reach approximately the same con-
centration (350 ng/ml, 0.2 µM). C. S2 cells were transfected 
with ub-Gal4-NT or control vector and treated with the 50 
control mice. * p<0.05 vs. control mice; t p<0.05 vs. mice 
with olive oil only. B. Male Nr1+ and NT_;_ mice (n=4) on 
normal chow were fasted overnight. Mice were injected with indicated dsRNA and cell lysates were analyzed as in (a). 
Inactivation of Capability (Capa, CG15520), the Pyroki-
nin-1 in Drosophila, alters the levels of p-AMPK in neither 
the presence nor the absence of NT (left panel), indicating 
that NT prevents AMPK activation independently of Pyro-
kinin. Capa RNAi efficiency was monitored by real time-
PCR (right panel).* p<0.05 vs. control dsRNA. D. Midguts 
of 3rd instar larvae from the indicated genotypes were 
stained with Bodipy to monitor the accumulation of lipid 
droplets. Left panel, wl 118 control midgut accumulates low 
level of lipid (100%, n=8). Middle panel, larval midgut 
constitutively expressing NT by the TK promoter (TK-NT) 
accumulates high levels of lipid (100%, n=8). Right panel, 
larval midgut co-expressing TK-NT and MyolA-
CG9918RNAi27539 accumulated much lower levels of lipid 
(87%, n=15) compared to TK-NT midgut (middle panel). E. 
Amino acid sequence alignment of mouse NTRl (SEQ ID 
either saline or SR 48692 (2.5 mg/kg, i.p). Thirty min after 
the injection, mice were given olive oil (10 µ1/g) by oral 
gavage and then sacrificed. The proximal small bowel was 
55 excised and TG content measured. *p<0.05 vs. saline in 
NT+/+ and NT-1- mice; t p<0.05 vs. olive oil only in NT+/+ 
mice; t p<0.05 vs. olive oil only in Nr1+ mice. C. Weekly 
body weight was measured in male wild type C57BL/6 mice 
fed HFD and treated with SR 48692 (2.5 mg/kg diluted in 
60 diH20 and administered by oral gavage twice a day) or 
vehicle (vehicle n=12; SR 48692 n=13). BW slopes were 
compared: * p<0.05 vehicle vs. SR treatment. D. Weekly 
food intake was measured in male wild type C57BL/6 mice 
(n=l2-13) fed HFD and chronically treated with either SR 
65 48692 or vehicle. Analyses of either cumulative (left panel) 
or weekly (right panel) food intake did not show a significant 
difference. All data are mean+/-SD. 
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FIGS. 14A-C show graphs and images illustrating that 
FFA activates AMPK signaling and increases NT secretion. 
A. Plasma NT of male C57BL/6 mice (5-mo-old, n=5) 1 h 
after olive oil (00) oral gavage. *p<0.05 vs. NC; n=5. B. 
NT EIA (upper panels) and western blotting (lower panels) 5 
on BON cells treated with or without OA for 1 h. C. NT EIA 
(upper panels) and western blotting (lower panels) on 
QGP-1 cells treated with or without OA for 1 h. *p<0.05 vs. 
control; n=6. All data are mean+/-SD. 
FIGS. 15A-B show graphs and images illustrating that 10 
FFARl and FFAR4 agonists increaseAMPK activity. A. NT 
IF (left panel), NT EIA (middle panel, *p<0.05 vs. control) 
and western blotting (right panel) of STC-1 cells. B. Real-
time PCR. GAPDH was used as the internal control (BON 
cell expression was arbitrarily set at 1). All data are mean+/- 15 
SD. 
10 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a," "an," and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
As used herein, the term "about," when referring to a 
FIGS. 16A-D show graphs and images illustrating Cross-
talk of AMPK and mTORCl signaling. A. Diagram of 
cross-talk of AMPK and mTORCl signaling. B. Western 
blot analysis of BON cells treated with or without AICAR 
(left panel) or 1 mM AICAR and CC (10 µM) (right panel) 
for 3 h. C. NT EIA (upper panel) and western blotting (lower 
panel) on BON cells expressing control vector and myc-
raptor S722A/S792A treated withAICAR (1 mM) for 3 h. D. 
NT EIA (upper panel) and western blotting (lower panel) on 
BON cells expressing control vector and NTC and TSC2 
siRNA treated with AICAR (1 mM) for 3 h. *p<0.05 vs. 
control in vector, tp<0.05 vs. AI CAR in vector (C); *p<0.05 
20 value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±20%, in some embodi-
ments ±10%, in some embodiments ±5%, in some embodi-
ments ±1%, in some embodiments ±0.5%, and in some 
25 embodiments ±0.1 % from the specified amount, as such 
variations are appropriate to perform the disclosed method. 
vs. control in NTC siRNA, tp<0.05 vs. control in NTC 
siRNA, t p<0.05 vs. AICAR in NTC siRNA (D). n=6. All 30 
data are mean+/-SD. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
35 and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 40 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 45 
this document, including definitions, will control. 
Some of the polynucleotide and polypeptide sequences 
disclosed herein are cross-referenced to GENBANK®/ 
GENPEPT® accession numbers. The sequences cross-ref-
erenced in the GENBANK®/GENPEPT® database are 50 
expressly incorporated by reference as are equivalent and 
related sequences present in GENBANK®/GENPEPT® or 
other public databases. Also expressly incorporated herein 
The presently disclosed subject matter relates to a method 
for predicting increased risk of obesity in a non-obese 
subject. More particularly, the presently disclosed subject 
matter relates to a method of predicting increased risk of 
obesity in a non-obese subject by determining a level of 
neurotensin expression in a biological sample from the 
subject and comparing the level of neurotensin expression in 
the sample with a control level. 
In some embodiments of the presently disclosed subject 
matter, a method of predicting increased risk of obesity in a 
non-obese subject is provided. The method includes the 
steps of contacting a biological sample from the subject with 
a probe for neurotensin to determine the amount of neuro-
tensin in the biological sample; comparing the amount of 
neurotensin to a control level; and determining that the 
subject has an increased risk of obesity if there is a mea-
surable difference in the amount of neurotensin in the sample 
as compared to a control level, wherein an increased neu-by reference are all annotations present in the GENBANK®/ 
GENPEPT® database associated with the sequences dis-
closed herein. Unless otherwise indicated or apparent, the 
references to the GENBANK®/GENPEPT® database are 
references to the most recent version of the database as of 
the filing date of this Application. 
55 rotensin level is predictive for an increased risk of becoming 
obese. 
While the terms used herein are believed to be well 60 
understood by one of ordinary skill in the art, definitions are 
set forth to facilitate explanation of the presently-disclosed 
subject matter. 
In some embodiments, the method further includes the 
steps of measuring the phosphorylation level of AMPK in 
the biological sample; and comparing the measured phos-
phorylation level to a control level, wherein a decreased 
level of phosphorylation is predictive for an increased risk of 
becoming obese. A non-limiting example of neurotensin is 
pro-neurotensin. In some embodiments of the presently 
disclosed subject matter, the risk of becoming obese is Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
65 independent of baseline body mass index (BMI). 
As used herein, the term "obesity" or "obese" refers to a 
medical condition in which excess body fat has accumulated 
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The "amount" oftest biomarker(s) determined refers to a 
qualitative (e.g., present or not in the measured sample), 
quantitative (e.g., how much is present), or both measure-
ment of the text biomarker(s) (e.g., neurotensin). The "con-
trol level" is an amount (including the qualitative presence 
or absence) or range of amounts of biomarker(s) found in a 
comparable biological sample in non-obese subjects who did 
not become obese. In some embodiments, the control level 
can refer to reference value or a standard sample that is 
to the extent that it may have an adverse effect on health, 
leading to reduced life expectancy and/or increased health 
problems. Obesity is typically determined by assessing the 
body mass index (BMI), a measurement which compares 
weight and height. For example, people are often defined as 5 
underweight if BMI is below about 18, normal if BMI is 
between about 18 and 25, overweight if their BMI is 
between about 25 and 30, and obese when BMI is greater 
than about 30. The term "non-obese" refers to underweight, 
normal, and overweight. 10 provided based on information obtained about the amounts 
of the biomarker(s) found in comparable biological 
sample(s) from non-obese subjects who did not become 
obese. 
The phrase "predicting increased risk" as used herein 
refers to methods by which the skilled artisan can predict the 
course or outcome of the treatment for a condition in a 
subject. It does not refer to the ability to predict the course 
or outcome of a condition with 100% accuracy, or even that 15 
a given course or outcome is predictably more or less likely 
to occur based on the presence, absence or levels of test 
biomarkers. Instead, the skilled artisan will understand that 
the term refers to an increased probability that a certain 
course or outcome will occur; that is, that a course or 20 
outcome is more likely to occur in a subject exhibiting a 
given condition, when compared to those individuals not 
exhibiting the condition ( e.g., biomarker level). For 
example, in individuals not exhibiting the condition, the 
chance of a given outcome may be about 3%. In certain 25 
embodiments, a prognosis is about a 5% chance of a given 
outcome, about a 7% chance, about a 10% chance, about a 
12% chance, about a 15% chance, about a 20% chance, 
about a 25% chance, about a 30% chance, about a 40% 
chance, about a 50% chance, about a 60% chance, about a 30 
75% chance, about a 90% chance, or about a 95% chance. 
The skilled artisan will understand that associating a 
prognostic indicator with a predisposition to an adverse 
outcome is a statistical analysis. For example, a biomarker 
level (e.g., quantity of expression in a sample) of greater 35 
than a control level in some embodiments can signal that a 
subject is more likely to develop obesity in a non-obese 
subject than subjects with a level less than or equal to the 
control level, as determined by a level of statistical signifi-
cance. Additionally, a change in marker concentration from 40 
baseline levels can be reflective of subject prognosis, and the 
degree of change in marker level can be related to the 
severity of adverse events. Statistical significance is often 
determined by comparing two or more populations, and 
determining a confidence interval and/or a p value. See, e.g., 45 
Dowdy and Wearden, Statistics for Research, John Wiley & 
Sons, New York, 1983, incorporated herein by reference in 
its entirety. Preferred confidence intervals of the present 
subject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 
99.9% and 99.99%, while preferred p values are 0.1, 0.05, 50 
0.025, 0.02, 0.01, 0.005, 0.001, and 0.0001. 
In other embodiments of the presently-disclosed subject 
matter, a threshold degree of change in the level of a 
prognostic or diagnostic biomarker can be established, and 
the degree of change in the level of the indicator in a 55 
biological sample can simply be compared to the threshold 
degree of change in the level. A preferred threshold change 
in the level for markers of the presently-disclosed subject 
matter is about 5%, about 10%, about 15%, about 20%, 
about 25%, about 30%, about 50%, about 75%, about 100%, 60 
and about 150%. 
In certain embodiments, a diagnostic or prognostic bio-
marker is correlated to a condition or disease by merely its 
presence or absence. In other embodiments, a threshold level 
of a diagnostic or prognostic biomarker can be established, 65 
and the level of the indicator in a subject sample can simply 
be compared to the threshold level. 
As used herein, the term "subject" refers to an animal, 
including a mammal, such as a human being. 
With regard to the step of providing a biological sample 
from the subject, the term "biological sample" as used herein 
refers to any body fluid or tissue potentially comprising the 
presently-disclosed biomarkers, including neurotensin. In 
some embodiments, for example, the biological sample can 
be a blood sample, a serum sample, a plasma sample, or 
sub-fractions thereof. In some embodiments, the biological 
sample is an adipose tissue biopsy, such as a tissue biopsy 
containing adipocytes or cells suspected to be adipocyte. 
Turning now to the step of identifying one or more 
markers in the biological sample, various methods known to 
those skilled in the art can be used to identify the one or 
more markers in the provided biological sample. In some 
embodiments, determining the amount of biomarkers in 
samples comprises using an RNA measuring assay to mea-
sure mRNA encoding biomarker polypeptides in the sample 
and/or using a protein measuring assay to measure amounts 
of biomarker polypeptides in the sample. 
In certain embodiments, the amounts of biomarkers can 
be determined by probing for mRNAofthe biomarker in the 
sample using any RNA identification assay known to those 
skilled in the art. Briefly, RNA can be extracted from the 
sample, amplified, converted to cDNA, labeled, and allowed 
to hybridize with probes of a known sequence, such as 
known RNA hybridization probes (selective for mRNAs 
encoding biomarker polypeptides) immobilized on a sub-
strate, e.g., array, or microarray, or quantitated by real time 
PCR (e.g., quantitative real-time PCR). Because the probes 
to which the nucleic acid molecules of the sample are bound 
are known, the molecules in the sample can be identified. 
With regard to determining amounts of biomarker poly-
peptides in samples, in some embodiments, mass spectrom-
etry and/or immunoassay devices and methods can be used 
to measure biomarker polypeptides in samples, although 
other methods are well known to those skilled in the art as 
well. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019, 
944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885, 
527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 
5,480,792, each of which is hereby incorporated by refer-
ence in its entirety. Immunoassay devices and methods can 
utilize labeled molecules in various sandwich, competitive, 
or non-competitive assay formats, to generate a signal that 
is related to the presence or amount of an analyte of interest. 
Additionally, certain methods and devices, such as biosen-
sors and optical immunoassays, can be employed to deter-
mine the presence or amount of analytes without the need for 
a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 
5,955,377, each of which is hereby incorporated by refer-
ence in its entirety. 
Thus, in certain embodiments of the presently-disclosed 
subject matter, the marker peptides are analyzed using an 
immunoassay. The presence or amount of a marker (e.g., 
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As used herein, the terms "treatment" or "treating" relate 
to any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
The terms relate to medical management of a subject with 
neurotensin or pro-neurotensin) can be determined using 
antibodies or fragments thereof specific for each marker and 
detecting specific binding. For example, in some embodi-
ments, the antibody specifically binds pro-neurotensin, 
which is inclusive of antibodies that bind the full-length 
peptide, fragments thereof, or phosphorylated forms thereof. 
In some embodiments, the antibody is a monoclonal anti-
body. 
5 the intent to substantially cure, ameliorate, stabilize, or 
substantially prevent a condition of interest ( e.g., disease, 
pathological condition, or disorder), including but not lim-
ited to prophylactic treatment to preclude, avert, obviate, 
forestall, stop, or hinder something from happening, or 
10 reduce the severity of something happening, especially by 
advance action. 
Any suitable immunoassay can be utilized, for example, 
enzyme-linked immunoassays (ELISA), radioimmunoas-
says (RIAs), competitive binding assays, and the like. Spe-
cific immunological binding of the antibody to the marker 
can be detected directly or indirectly. Direct labels include 
fluorescent or luminescent tags, metals, dyes, radionuclides, 
15 
and the like, attached to the antibody. Indirect labels include 
various enzymes well known in the art, such as alkaline 
phosphatase, horseradish peroxidase and the like. 
In some embodiments, the amount of pro-neurotensin is 
detected by a technique comprising RNA measuring assays 20 
and protein measuring assays. In some embodiments, an 
RNA measuring assay comprises real time reverse transcrip-
tion polymerase chain reaction. 
In some embodiments, the obesity is prevalent obesity. In 
some embodiments, the obesity is prevalent abdominal 25 
obesity. In some embodiments, the obesity is new-onset 
obesity. 
Further provided in some embodiments of the presently 
disclosed subject matter, is a method of administering to 
non-obese subject preventative treatment for obesity. In 30 
some embodiments, the preventative treatment includes 
administration of a neurotensin inhibitor. 
In some embodiments, the presently disclosed subject 
matter further provides a method of detecting reduced 
intestinal fat absorption in a subject. The method includes 35 
the steps of contacting a biological sample from the subject 
with a probe for neurotensin to determine the amount of 
neurotensin in the biological sample; comparing the amount 
of neurotensin to a control level; and determining that the 
subject has reduced intestinal fat absorption if there is a 40 
measurable difference in the amount of neurotensin in the 
sample as compared to the control level, wherein a 
decreased neurotensin level is indicative of reduced intesti-
nal fat absorption. In some embodiments, the method further 
includes the steps of measuring the phosphorylation level of 45 
AMPK in the biological sample; and comparing the mea-
sured phosphorylation level to a control level, wherein an 
elevated phosphorylation level is indicative of reduced intes-
tinal fat absorption. 
Still further, in some embodiments of the presently dis- 50 
closed subject matter, a method of preventing and/or treating 
obesity in a subject in need thereof is provided. The method 
includes administering to the subject an effective amount of 
an agent that inhibits neurotensin. In some embodiments, the 
method further includes administering a pharmaceutical 55 
composition including an agent that inhibits neurotensin and 
a pharmaceutically acceptable carrier. In some embodi-
ments, the agent is a neurotensin inhibitor. In some embodi-
ments, the agent is a neurotensin receptor antagonist. In 
some embodiments, the agent is a small molecule. In some 60 
embodiments, the agent is a peptide. In some embodiments, 
the agent is neurotensin siRNA. 
Non-limiting examples of neurotensin receptor antago-
nists are those disclosed in Gully et al., 1993 and Gully et al., 
1997, including SR 48692 and SR 142948A. Gully et al., 65 
1993, and Gully et al., 1997 are incorporated by reference in 
their entirety. 
As such, the terms treatment or treating include, but are 
not limited to: inhibiting the progression of a condition of 
interest; arresting or preventing the development of a con-
dition of interest; reducing the severity of a condition of 
interest; ameliorating or relieving symptoms associated with 
a condition of interest; causing a regression of the condition 
of interest or one or more of the symptoms associated with 
the condition of interest; and preventing a condition of 
interest or the development of a condition of interest. 
The terms includes active treatment, that is, treatment 
directed specifically toward the improvement of a condition 
of interest, and also includes causal treatment, that is, 
treatment directed toward removal of the cause of the 
condition of interest. In addition, the terms includes pallia-
tive treatment, that is, treatment designed for the relief of 
symptoms rather than the curing of the condition of interest; 
preventative treatment, that is, treatment directed to mini-
mizing or partially or completely inhibiting the development 
of the associated condition of interest; and supportive treat-
ment, that is, treatment employed to supplement another 
specific therapy directed toward the improvement of the 
associated condition of interest. 
Neurotensin (NT), a 13-amino acid peptide, or trideca-
peptide, predominantly localized in specialized enteroendo-
crine (EE) cells of the small bowel and released by fat 
ingestion, facilitates fatty acid (FA) translocation in rat 
intestine, and stimulates growth of various cancers. NT, 
which is released from N-cells of the small bowel in 
response to intraluminal fats, facilitates free fatty acid (FFA) 
absorption from the intestinal lumen, stimulates pancreati-
cobiliary secretions, decreases gastric motility, and contrib-
utes to lipid metabolism and glucose control, although its 
precise role in these processes has not been previously 
delineated. The effects of NT are mediated through three 
known NT receptors (NTRl, 2 and 3). Increased fasting 
plasma levels of pro-NT (a stable NT precursor fragment 
produced in equimolar amounts relative to NT) are associ-
ated with increased risk of diabetes, cardiovascular disease 
and mortality; however, a role for NT as a causative factor 
in these diseases is unknown. In the past, NT has been 
considered as a satiety hormone which could potentially 
curb appetites. Therefore, previous studies have proposed 
using NT analogues, instead of inhibitor, as a possible 
treatment for obesity. However, in some embodiments of the 
presently disclosed subject matter, a preventive and/or treat-
ment method for obesity is provided by administering agents 
that blocks the effects of neurotensin. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the presently disclosed subject matter. 
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EXAMPLES 
Example 1 
The current study shows that NT-deficient mice demon- 5 
strate significantly reduced intestinal fat absorption and are 
protected from obesity, hepatic steatosis, and insulin resis-
tance associated with high fat consumption. It further dem-
onstrates that NT attenuates the activation of AMP-activated 
protein kinase (AMPK) and stimulates FA absorption in 10 
mice and in cultured intestinal cells, and that this occurs 
through a mechanism involving NTRl and NTR3/sortilin in 
vitro. Consistent with the findings in mice, expression of NT 
in Drosophila midgut EE cells results in increased lipid 
accumulation in the midgut, fat body, and oenocytes (spe- 15 
cialized hepatocyte-like cells) and decreasedAMPK activa-
tion. In humans, this study shows that both obese and 
insulin-resistant subjects have elevated plasma concentra-
tions of pro-NT, and in longitudinal studies among non-
obese subjects, high levels of pro-NT denote a doubling of 20 
the risk of developing obesity later in life. This study directly 
link NT with increased fat absorption and obesity and 
suggest that NT may provide a prognostic marker of future 
obesity and a potential target for prevention and treatment. 
Methods 25 
Reagents. 
16 
old) were obtained from Taconic. After one week acclima-
tion, mice were placed in individual cages, started on HFD, 
and after one week were divided into 2 groups one of which 
received SR 48692 ( dissolved in sterile diH20 by brief 
sonication, 2.5 mg/kg body weight31 - 33 and the other vehicle 
twice/day (8 am and 8 pm) by gavage. Mice were weighed 
and food intake was measured weekly. 
Human Intestinal Samples. 
Surgical samples of duodenum and colon were obtained 
from de-identified donors through the Markey Cancer Cen-
ter Biospecimen and Tissue Procurement Shared Resource 
Facility. All samples were obtained after informed consent 
according to a protocol approved by the Institutional Review 
Board of the University of Kentucky Medical Center 
(UKMC). Freshly-resected duodenum and colon specimens 
were placed in cold (4° C.) Dulbecco's Modified Eagle's 
Medium (DMEM) (Sigma-Aldrich) supplemented with 10% 
fetal bovine serum (FBS) (Sigma-Aldrich), 2% penicillin/ 
streptomycin (20,000 U/mL penicillin, 20 mg/mL strepto-
mycin) (Sigma-Aldrich), and 1.0 µg/mL Fungizone (Life 
Technologies). Tissues were processed within one hour after 
resection; the mucosa! layer was sharply dissected from the 
underlying seromuscular layer and collected in multiple 3 to 
5 mm sections for western blotting. 
Cell Culture. 
FHs74Int, purchased from ATCC (Manassas, Va.), is a 
human small intestinal epithelial cell line maintained in 
Hybri-Care Medium ATCC 46-X supplemented with 30 
ng/ml epidermal growth factor (Sigma-Aldrich) and 10% 
30 FBS. RIE-1 is a rat intestinal epithelial cell line maintained 
in DMEM containing 2 mM L-glutamine, 4500 mg/L glu-
cose and 10% FBS. The human colon cancer cell line, 
Caco-2 (ATCC), is maintained in Minimum Essential 
Medium (MEM) (Sigma-Aldrich) supplemented with 15% 
Antibodies for p-AMPKa (2535), AMPKa (2532), and 
LKBl (3050) were from Cell Signaling Technology (Dan-
vers, Mass.). Antibodies for NTRl (sc-374492 for western 
blotting and sc-25042 for IHC) and NTR3 (sc-30217 for 
IHC) were from Santa Cruz Biotechnology (Dallas, Tex.). 
CaMKK2 (ab168818), NTR3 (ab166490 for western blot-
ting), and F4/80 (ab100790) antibodies were from Abeam 
(Cambridge, Mass.). FLAG (F1804) and ~-actin (A5316) 
antibodies were from Sigma-Aldrich (St. Louis, Mo.). ON-
TARGETplus SMARTpool (LKBl, CaMKK2, NTRl, 
NTR3) and ON-TARGETplus Non-targeting Control Pool 
siRNA were purchased from GE Dharmacon (Lafayette, 
Colo.). AICAR was from Cayman (Ann Arbor, Mich.). 
Oleate sodium, NT, glucose and human insulin were from 40 
Sigma. Deuterated oleic acid (CLM-460-PK) was obtained 
from Cambridge Isotope Laboratories (Tewksbury, Mass.). 
SR 48692 was from Tocris (Minneapolis, Minn.). siRNA 
(RNAiMAX) and plasmid (Lipofectamine® LTX Reagent 
with PLUS™ Reagent) transfection reagents, and Trizol 45 
were from Life Technologies (Grand Island, N.Y.). pSG5-
FLAG-CaMKK2 rat FL was a gift from Anthony Means 
(Addgene plasmid #32449) (Cambridge, Mass.). Primers for 
RT-PCR were from Integrated DNA Technologies (Coral-
ville, Iowa). 
35 FBS. The human liver cancer cell line, HepG2 (ATCC), is 
maintained in MEM with 10% FBS. FHs 74 Int cells were 
tested for authentication via STR profiling in April 2015 by 
Genetica DNA Laboratories (LabCorp Specialty Testing 
Group; Burlington, N.C.) using the commercially available 
PowerP!ex® 16HS amplification kit (Promega Corporation) 
and GeneMapper ID v3.2.1 software (Applied Biosystems). 
Authentication was confirmed by a 100% match in com-
parison to the reference STR profile fromATCC (FHs 74 Int; 
ATCC® CCL-241™). The cell lines are not listed in the 
ICLAC database. In addition, both cell lines were tested for 
mycoplasma contamination via PCR (e-Myco Plus kit; 
iNtRON Biotechnology) and were found to be negative. 
Western Blotting. 
Tissues and cells were lysed with lysis buffer (Cell 
Mice. 
50 Signaling Technology), and equal amounts of protein were 
resolved on 4-12% NuPAGE BisTris gels (Life Technolo-
gies) and electrophoretically transferred to polyvinylidene 
difluoride (PVDF) membranes; the membranes were incu-
All procedures were approved by the Institutional Animal 
Care and Use Committee of the University of Kentucky. NT 
homozygous (NT-1-) mice and their wild type littermates 
(NT+1+) were bred from NT heterozygous (NT+1-) mice and 55 
randomly grouped for all experiments. Mice were main-
tained on 12-h light-dark cycles and provided with food and 
water ad libitum. For diet-induced obesity studies, male and 
female NT+!+ and NT-1- mice were placed on a 60% HFD or 
10% LFD (catalogue no. D12492 and D12450B, respec- 60 
tively; Research Diets, New Brunswick, N.J.) at weaning for 
22-25 wks. Body weight and food intake were measured 
weekly. Food intake was measured for each cage (3-5 mice 
per cage) and divided by mouse number to obtain total 
grams consumed per mouse per week. All mice used were 65 
4-6 months old unless otherwise indicated. For chronic SR 
48692 treatment on HFD-fed mice, C57BL/6 mice (8 weeks 
bated with primary antibodies overnight at 4 ° C. followed by 
secondary antibodies conjugated with horseradish peroxi-
dase. Membranes were developed using chemiluminescence 
(ECL) Western Blotting System from GE Healthcare Life 
Science (Piscataway, N.J.) and Thermo Scientific (Waltham, 
Mass.). 
Histology and Immunohistochemistry (IHC). 
Epididymal adipose, liver and intestinal tissues were fixed 
in 10% neutral-buffered formalin, embedded in paraffin, and 
sectioned (5 µm). H&E staining was performed using stan-
dard techniques. Adipocyte size was measured as described 
previously. Briefly, sections of epididymal adipose tissue 
from each mouse were photographed under xl00 magnifi-
cation. In a square measuring 700x700 µm (x- and y-axis, 
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NT Enzymeimmunoassay (EIA). 
Fifty µl of media were used to measure NT levels using 
NT EIA Kit from Phoenix Pharmaceuticals (Burlingame, 
Calif.) as described previously30-33 . 
Glucose and Insulin Tolerance Tests. 
Glucose (GTT) and insulin (ITT) tolerance tests were 
performed on 6 h-fasted mice fed HFD. Glucose values were 
measured using One Touch Ultra from LifeScan (Wayne, 
Pa.) by tail snip. Glucose (1.5 g/kg body weight) and human 
respectively), adipocyte size and number were measured 
using NIS Elements BR.3.10 software. A criterion for inclu-
sion of measurements was a circularity of adipocytes supe-
rior to 0.33 [ shape of cells; from O (thin shape) to 1 (perfect 
circle)]. For oil red O (ORO) staining, liver and small bowel 5 
tissues were fixed in 10% neutral-buffered formalin, equili-
brated in 30% sucrose and embedded in OCT compound and 
snap-frozen in liquid N2 . Frozen sections were stained with 
ORO (Sigma-Aldrich) for lipid deposition using standard 
methods. IHC was performed and visualized by Dako En Vi-
sion Systems (Burlington, Ontario, Canada) following the 
product instruction. 
10 insulin (0.75 U/kg body weight) were injected intraperito-
neally (i.p.) after baseline glucose levels established in each 
mouse. Glucose was measured at 15, 30, 60 and 120 min 
after injection. 
Metabolic Studies. 
Whole body composition parameters were measured by 
EchoMRI-5000 Whole Body Composition (Echo Medical 
System, Houston, Tex.) using Magnetic Resonance Relax-
ometry to precisely measure total body fat, lean mass, body 
fluids and total body water in conscious mice. A TSE 
Reverse transcription-polymerase chain reaction (RT-
PCR). Total RNA was isolated from cells using RNeasy Kit 15 
(Qiagen, Valencia, Calif.) according to the manufacturer's 
instructions. RT-PCR analysis of NTRl, 2 and 3 was per-
formed using cDNA synthesized from 1 µg of total RNA. 
~-actin was used as the internal control. The primers 
included: human NTRl: 20 LabMaster indirect calorimetry system (TSE-Systems Inc., 
Chesterfield, Mo.) was used to simultaneously quantify 
energy expenditure, energy intake, locomotor activity, and 
respiratory exchange ratio (RER). Mice were acclimated to (SEQ ID NO, 3) 
5'-TCATCGCCTTTGTGGTCTGCT-3' 
and 
(SEQ ID NO, 4) 25 
5'-TGGTTGCTGGACACGCTGTCG-3'; 
human NTR2, 
(SEQ ID NO, 5) 
5'-GTCTCCTCAGCTTCATCGTAT-3' 
and 30 
(SEQ ID NO, 6) 
5'-TCCCCAAAGCCTGAAGCTGTA-3'; 
human NTR3 (SORTl), 
(SEQ ID NO, 7) 35 
5'-AGAATGGTCGAGACTATGTTG-3' 
and 
(SEQ ID NO, 8) 
5'-AAGAGCTATTCCAAGAGGTCC-3'; 
40 
rat ntrl: 
(SEQ ID NO, 9) 
5'-GAGAAGCCCCCAAAATTCTC-3' 
and 
(SEQ ID NO, 10) 
45 
5'-CAAGGACCCAGTGCAGGTAT-3'; 
rat ntr2: 
(SEQ ID NO, 11) 
5'-ACTCGCTCATCTTCGCATTT-3' 
and 
50 
(SEQ ID NO, 12) 
5'-TGGGACCACACGAAGTTGTA-3'; 
rat ntr3 (Sortl), 
(SEQ ID NO, 13) 
5'-TTTCAAGCTGTGCTTTGTGG-3' 55 
and 
(SEQ ID NO, 14) 
5'-AGTTCTCTGAACGGGAGCAA-3'. 
13-actin, 60 
(SEQ ID NO, 15) 
5'-TCACCAACTGGGACGACATG-3' 
and 
(SEQ ID NO, 16) 
5'-ACCGGAGTCCATCACGATG-3'. 65 
The PCR products were analyzed on a 2% agarose gel. 
the chambers for 7 d, to permit recovery from the weight loss 
initially experienced by obese mice. Recordings were per-
formed for 5 d, yielding three full 24 h periods of data. 
Feeding and activity data were collected continuously; 0 2 
and CO2 levels for energy expenditure and RER calculations 
were collected at 30 min intervals. Resting energy expen-
diture values were calculated from data collected between 9 
AM and 6 PM, filtered to remove points at which activity 
was greater than 150 counts for that interval. 
For hepatic triglyceride and cholesterol measurements, 
liver tissues were collected and triglyceride and cholesterol 
extracted as described previously and analyzed by LC-MS 
coupled with electrospray ionization tandem using stable 
isotope dilution performed on AB Sciex 4000 Q-Trap instru-
ments. Plasma glucose was analyzed using a Glucose Colo-
rimetric Assay Kit (BioVision, Inc., Milpitas, Calif.) and 
insulin using a Mouse Insulin ELISA kit (Mercodia Inc, 
Winston Salem, N.C.). Plasma insulin and glucose levels 
were measured in mice (fed standard chow after weaning) 
that had been fasted overnight and subsequently given 
glucose (2 g/kg body weight) by gavage (i.e., oral glucose 
tolerance test). Blood was collected from tail snips before (0 
min) or 15, 30, 60 and 120 min after gavage. Insulin and 
glucose levels were measured as described above. Plasma 
insulin levels were also determined in mice that were either 
fasted for 16 h or fasted for 16 h with refeeding for 4 h; 
blood was collected from the IVC. For fecal triglyceride 
assay, mice were housed in individual cages for 4 d; day 4 
fecal samples were dried and ground. Lipid was extracted 
from 50 mg of fecal samples and triglyceride measured by 
LC-MS and normalized to fecal weight. 
Body Length Measurements. 
Anal-nasal length was measured following isoflurane 
anesthesia of NT+/+ and NT_;_ mice. 
Fecal Weight Measurements. 
NT+/+ and NT-1- mice fed HFD for 24 wks were separated 
into individual cages and fecal pellets were collected and 
weighed daily for 4 d. Fecal weights from day 4 were 
averaged for wild type and NT deficient mice. 
Small intestinal characterization. The entire small intes-
tine (SI), from the gastric pylorus to the ileocecal valve was 
dissected from anesthetized male NT_;_ and NT+/+ mice. 
The SI length was measured and then opened longitudinally, 
washed in cold saline to clear the luminal contents, dried 
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briefly on a paper towel and weighed. The SI was divided 5 
cm distal from the pyloric junction and the jejunoileum was 
divided into equal proximal and distal fragments. Proximal 
fragments were fixed in 10% neutral-buffered formalin for 
24 h, and "Swiss rolls"41 were sectioned (5 µm) for H&E and 5 
IHC staining. H&E stained sections were imaged on an 
Aperio ScanScope XTTM slide scanner at 20x. Crypt counts 
and villus height were determined using Aperio ImageScope 
vll.2.0.780 software. Crypts in a 1 mm field were quanti-
fied; 10 fields were analyzed per section. Villus height was 
10 
measured from 10 well-oriented villi on each slide. 
Lipid Absorption Studies. 
For olive oil administration and ORO analysis, mice were 
fasted overnight and fed the olive oil (17 µ1/g body weight) 
20 
gies) for 15 min. BSA-conjugated oleate sodium was also 
used to treat cells for 1 h; cells were then stained with 
BODIPY® 493/503 ( 4,4-Difluoro-l ,3,5,7,8-Pentamethyl-4-
Bora-3a,4a-Diaza-s-Indacene) (Life Technologies). Images 
were observed under an FVl000 Olympus confocal micro-
scope with a x60, 1.35-numerical aperture oil objective 
(Olympus, Tokyo, Japan). Images were analyzed with 
Olympus FV10-ASW2.1 software. To quantify green inten-
sity, 3 images were taken at consistent conditions and 10 
cells from each image were analyzed using the area tool. For 
the lipid accumulation study, RIE-1 cells were pre-treated 
with or without NT at different concentrations for 30 min 
followed by combination of NT with BSA or BSA-conju-
gated oleate (0.1 mM) overnight. Cells were collected, lysed 
and triglyceride content was measured by Triglyceride 
Determination Kit (Sigma-Aldrich). All experiments were 
carried in serum-free medium and fatty acid-free BSA was 
used at 0.1%. 
For acute SR 48692 treatment, male wild type C57BL/6 
by gavage. The mice were sacrificed before ( control), 30 min 
and 60 min after the gavage. The intestine was resected from 15 
the ligament of Treitz to the ileocecal junction, divided into 
proximal, middle, and distal segments of equal length and 
washed with cold saline. The proximal intestine was pro-
cessed for frozen sections and ORO staining by standard 
protocol. 20 mice (16 weeks old) obtained from Taconic (Hudson, N.Y.) 
were acclimated for one week, randomly divided into con-
trol, olive oil, and olive oil+SR 48692 groups (n=8) and 
fasted overnight. SR 48692 was dissolved in DMSO (50 
For 13C18-OA experiments, mice were fasted overnight 
and fed 13C18-OA (480 µM/g body weight) mixed in olive 
oil (10 µ1/g body weight) by gavage. Mice were sacrificed at 
0 and 30 min after gavage. Proximal intestines were col-
lected. To detect plasma level of 13C18-OA, mice were 25 
given 13C18-OA as above and blood was collected from tail 
snip before (0 h), 1, 2 and 3 h after gavage. Lipid was 
extracted from proximal intestines and plasma and analyzed 
for 13C18-OA enrichment by direct infusion nanospray FT-
MS (Orbitrap Fusion™ Tribrid™ Mass Spectrometer, 30 
Thermo Scientific, Waltham, Mass.) modified from a previ-
ous method. Briefly, aliquots of the lipid extracts were first 
diluted twenty-fold in isopropanol:chloroform:methanol 
4:2:1 before introduction into TriVersa NanoMate® (Ad-
vion, Inc., Ithaca, N.Y.) and analyzed on the Orbitrap Fusion 35 
in negative ion mode to estimate the appropriate amount of 
d34-OA to spike. Lipid extracts spiked with known concen-
tration of d34-OA in the same solvent system were analyzed 
again with the same FT-MS method. The nanospray condi-
tions on the Nanomate were as follows: 15 µl of sample 40 
injection, 16 min of delivery time, 0.4 psi of gas pressure, 
and 1.5 kV of negative applied voltage. The Orbitrap Fusion 
MS analysis conditions were as follows: mass resolution of 
450,000 with lock mass using internal calibrant, scan range 
of m/z 150-1600, % S-Lens RF Level of 60, 1.0e5 for AGC 45 
Target, 100 msec maximum injection time, and 10 averaged 
microscans. The ion transfer tube temperature was 275° C., 
and the experimental mass accuracy was ±-1 ppm. The 
unlabe-
led, 13C labeled, and d34-OA were assigned based on their 50 
respective accurate mass of 281.24860, 299.30899, and 
314.45574; unlabeled and 13C labeled OA were then quan-
tified against the internal d34-OA standard using their 
respective peak intensity. 
For NT "rescue" experiments, mice were fasted overnight 55 
and fed with or without the olive oil (17 µ1/g body weight) 
mg/ml) and diluted 1:100 in saline just prior to use. Mice 
were injected i.p. with SR 48692 (2.5 mg/kg)31 •33 or vehicle 
30 min prior to oral gavage of olive oil (10 µ1/g), sacrificed 
after an additional 30 min, and the distal half of the proximal 
intestine (see above) was used to determine TG content and 
for preparation of lysates for western blotting. This experi-
ment was repeated in male NT+/+ and NT-1- mice (7-mo-
old), and proximal intestinal TG was measured as described 
above. 
Drosophila Studies. 
Full-length human NT cDNA was inserted into an attB-
UAST backbone and the resultant transgene generated using 
an attP2 locus and PhiC31 integration system. UAS-AMPK 
and UAS-AMPKRNAi (v106200) lines have been 
described. UAS-AMPKRNAi line was also obtained from 
Bloomington Stock Center (TRiP #25931). These RNAi 
(TRiP #25931 and vl 06200) gave rise to similar phenotypes, 
thus AMPKRNAi25931 was used for most of the experi-
ments. Gr36C-Gal4, MyolA'5 -Gal4, voila-Gal4, and S106-
Gal4 have been described (FlyBase). MyolA-Gal4 is spe-
cifically expressed in enterocytes. In order to constitutively 
express NT in gut EE cells, a gut EE cell-specific TK 
promoter (2.0 kb )28 •29 was cloned into attB-UAST lacking 
Gal4 binding sites followed by insertion of full-length NT 
cDNA and the resulting plasmid (TK-NT) was used to 
generate a transgenic line by insertion at the VK5 attP locus. 
To express NT in EE cells and knock down CG9918 by 
RNAi in EC cells, the following genotype was used: yw; 
MyolA-Gal4/CG9918RNAi27539 ; TK-NT/+. The tub-
Gal80's was used in combination with the MyolA-Gal4 
(resulting in the genotype of Myo's) to temporarily control 
MyolA-Gal4 target gene expression, after shifting larvae to 
29° C. nonpermissive temperature 96 h after egg laying 
(AEL) or adult emerging. The present inventors combined 
the AMPK or AMPKRNAi allele with the RU486-inducible 
by gavage followed by i.p. injection of saline or NT (3600 
nmol/kg body weight) immediately after gavage. The mice 
were sacrificed 60 min after the gavage. Partial proximal 
intestine was processed for ORO staining as described above 
and partial for triglyceride quantification using a Triglycer-
ide Determination Kit (Sigma-Aldrich)38 . 
GeneSwitch Gal4 line: S106-Gal4, which is fat body-spe-
60 cific. Then, the present inventors grew larvae with either 
S106-AMPK or S106-AMPKRNAi to vehicle or RU486 
For in vitro FA absorption or lipid accumulation studies, 
FHs7 4 Int and RIE-1 cells were incubated with either bovine 
serum albumin (BSA) (Sigma-Aldrich) or BSA-conjugated 65 
BODIPY® FL C16 (4,4-Difluoro-5,7-Dimethyl-4-Bora-3a, 
4a-Diaza-s-Indacene-3-Hexadecanoic Acid) (Life Technolo-
(200 µM, Mifepristone, Sigma-Aldrich) containing food and 
examined the accumulation of lipid droplets in fat body or 
oenocytes from 3rd instar larvae. Fresh food was supplied 
every other day. For midgut immunostaining, midguts from 
3rd instar larvae or adults with specific genotypes were 
dissected in PBS then fixed with 4% formaldehyde in PBS 
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for 20 min. After permeabilization with PBT (PBS supple-
mented with 0.1% Triton Xl00), midguts were incubated 
with the indicated primary antibodies for 3 h and the 
corresponding secondary antibodies for 1 h sequentially, and 
washed with PBT for 3 times, 20 min per wash, following 5 
incubation. Antibodies used in this study: mouse anti-Pros 
(DSHB, MRlA); rabbit anti-NT (Abeam, ab43833). Midgut 
staining with Nile Red (Sigma-Aldrich) and larvae staining 
with Oil Red O (Sigma-Aldrich) were carried out after 
fixation. 1 o 
For western blot analysis, 15 entire gastrointestinal tracts 
from each genotype were lysed in SDS sample buffer [100 
mM NaCl, 50 mM Tris.RC! [pH8.0], 1.5 mM EDTA, 10% 
glycerol, 1 % NP-40, and protease inhibitor tablet (Roche, 
Indianapolis, Ind.)], and resolved by SDS-PAGE and trans- 15 
ferred to PVDF membranes (Millipore). Membranes were 
blocked and probed with primary antibodies to phospho-
AMPKa (Cell Signaling, #2535), total AMPKa (Abeam, 
ab80039,), and ~-tubulin (DSHB, E7, Iowa City, Iowa). 
After wash and incubation with secondary antibody (Jack- 20 
son ImmunoResearch, West Grove, Pa.), signals were 
detected using ECL. 
The method of HFD feeding for adult flies has been 
described. Briefly, flies (5 d after emerging) were collected 
and placed in bottles of normal food (cornmeal-yeast) and 25 
aged for an additional 5 d. This population was then split 
into two study groups, one on normal food and one on the 
HFD containing 20% (weight-to-volume ratio) coconut oil 
with the normal food. Flies were treated on HFD for 5 d. 
Treated adult flies were dissected and stained with Nile Red 30 
to examine lipid accumulation in the midgut. The other 
group of flies expressing NT by the EE cell-specific voila-
Gal4 was subjected to triglyceride measurement (Sigma-
Aldrich) after being given either HFD or normal food. 
voila-Gal4-wl 118 flies were used as control for this triglyc- 35 
eride experiment. Both male and female flies showed similar 
results in triglyceride concentration, which was increased by 
HFD. 
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CG8795, 
5'-GCTACGCCCTCATATTTATC-3' (SEQ ID NO, 21) 
and 
5'-GAGGTTATAGAGGTCCTGCG-3', (SEQ ID NO, 22) 
Capa, 
5'-ATGAAATCTATGTTGGTC-3' (SEQ ID NO, 23) 
and 
5'-CCAACGCGCGGGAAGGC-3', (SEQ ID NO, 24) 
Actin: 
5'-GCGTCGGTCAATTCAATCTT-3' 
and 
5'-AAGCTGCAACCTCTTCGTCA-3' 
(SEQ ID NO, 25) 
(SEQ ID NO, 26). 
NT Enzyme Immunoassay (EIA). 
Fifty µI of media from S2 cells transfected with ub-Gal4 
and UAST-NT were used to measure NT levels using NT 
EIA Kit from Phoenix Pharmaceuticals (Burlingame, Calif.) 
as described previously. 
LC-MS/MS Analysis of NT. 
NT was analyzed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using an LTQ-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, Waltham, Mass.) 
coupled with an Eksigent Nanoflex cHiPLC™ system (Eksi-
gent, Dublin, Calif.) through a nano-electrospray ionization 
source. NT in the NT EIA kit (Phoenix Pharmaceutical) was 
used as standard. S2 cells were transfected with ub-Gal4 and 
UAST-NT or the UAST vector control, and conditioned 
medium was harvested after 48 h for analysis. GI tracts 
(350/genotype) were dissected from wild-type (w1118) or 
Gr36C-NT 3rd instar larvae, methanol extracted, extracts 
were dried, and dissolved in 20 µI 0.1 % (v/v) formic acid in 
water for analysis. Samples were separated by reversed 
phase cHiPLC [ChromXP C18 column, 75 µm I.D.x15 cm 
length, Eksigent cat#804-00001; mobile phase A and B were 
0.1 % (v/v) formic acid in either water or acetonitrile, respec-
40 tively; flow rate, 300 nl/min]. LC-MS/MS data were 
acquired in an automated data dependent acquisition mode 
consisting of an Orbitrap MS scan (300-1800 m/z, 60,000 
resolutions) followed by MS/MS for fragmentation of the 7 
most abundant ions with the collision induced dissociation 
Drosophila S2 cells were cultured as previously 
described. dsRNA was synthesized against GFP (nucleotides 
6-606), CG9918 (nucleotides 11-570), CG8784 (nucleo-
tides - 72-478), CG8795 (nucleotides -203-343), and Capa 
(nucleotides 1-455) by the method described. Total RNA 
was extracted using Trizol reagent (Invitrogen). cDNA was 
synthesized using SuperScript III First Strand Synthesis kit 
(Invitrogen) from 1.0 µg total RNA according to the manu-
facturer's instructions. Quantitative RT-PCR reactions were 
carried out using SYBR Green PCR master mix reagents 
(Thermo) on the ABI StepOneP!us Real-Time PCR System 
(Applied Biosystems). Thermal cycling was conducted at 50 
95° C. for 30 sec, followed by 40 cycles of amplification at 
95° C. for 5 sec, 55° C. for 30 sec and 72° C. for 15 sec. The 
relative quantification of gene expression for each sample 
was analyzed by the llCt method. The following primers 
were used to amplify: 
CG9918, 
5'-GAGTTTCAACGGCGGAGGAA-3' (SEQ ID NO, 
and 
5'-AGCAGAGGAAGAAGCACACC-3', (SEQ ID NO, 
CG8784, 
5'-GGCGTGCTGGGTAATCTTAT-3' (SEQ ID NO, 
and 
5'-CAAAGGTTGTACAGCTCCTG-3', (SEQ ID NO, 
17) 
18) 
19) 
20) 
45 method. MS/MS fragments corresponding to NT1 - 13 were 
identified by comparison with the NT standard, and quan-
tified using the intensity of the NT3 + peak and NT standards 
(0.05, 0.1, 0.2, 0.5 fmole). 
Human Population Studies. 
The Malmo Diet and Cancer (MDC) study is a popula-
tion-based, prospective epidemiologic cohort of28,449 men 
(born 1923-1945) and women (born 1923-1950) from the 
city of Malmo in southern Sweden who underwent baseline 
examinations between 1991 and 1996. From this cohort, 
55 6,103 persons were randomly selected to participate in the 
MDC Cardiovascular Cohort (MDC-CC), which was 
designed to investigate the epidemiology of carotid artery 
disease, between 1991 and 1994. Fasted plasma samples at 
the baseline examination were available for analysis of 
60 pro-neurotensin (pro-NT) and successfully measured in a 
total of 4,632 participants in the MDC-CC. Of those, com-
plete data were available for BMI in 4,626, for waist 
circumference on 4,625, and for estimated degree of insulin 
resistance using the homeostasis model assessment of insu-
65 !in resistance (HOMA-IR) (fasting blood glucose concen-
trationxfasting plasma insulin concentration/22.5) in 4,468 
participants. BMI was defined as body weight in kilograms 
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divided by the square of height in meters and obesity as a 
BMh:30 kg/m2 . Abdominal obesity was defined as a waist 
circumference of 2:94 cm in males and 2:80 cm in females, 
according to the International Diabetes Federation defini-
tion. Insulin resistance was regarded present in subjects 
belonging to the top 25% of HOMA-IR values in the 
MDC-CC. 'New-Onset Obesity' is defined as obesity devel-
opment among non-obese MDC-CC participants who were 
re-examined and diagnosed with obesity after an average 
follow-up time of 16.5±1.5 years. Pro-NT was measured in 
stored fasting plasma specimens that were frozen to -80° C. 
immediately at the MDC-CC baseline exam using a recent 
chemiluminometric sandwich immunoassay to detect a pro-
NT precursor fragment (pro-NT 1-117) as described previ-
ously. Analyses of blood glucose and plasma insulin were 
carried out at the time of baseline examination at the 
Department of Clinical Chemistry, Malmo University Hos-
pital, which is attached to a national standardization and 
quality control system. Of the 4,626 subjects with baseline 
data on BMI and pro-NT, 2,900 subjects were re-examined 
with a new measurement of BMI after a mean follow-up of 
16.5±1.5 years. In analyses of incident obesity, the present 
inventors excluded 306 subjects who were obese already at 
the baseline examination, leaving a total of2,594 non-obese 
subjects for analysis of pro-NT in relation to incident 
obesity. All participants gave written informed consent, and 
the study was approved by the Ethical Committee at Lund 
University, Lund, Sweden. 
Statistical Analysis. 
Descriptive statistics including means and standard devia-
tions were calculated and represented using bar graphs. 
Linear mixed models were implemented to compare body 
weight and food intake levels over time as well comparisons 
24 
weight for fat composition and energy metabolism endpoints 
( energy expenditure, locomotor activity, energy intake, 
respiratory ratio). Model-building was performed to assess 
equality of slopes using two-way interactions between each 
5 of genotype and diet with the covariate as well as genotype 
and diet interactions. Two-sample t-test or the nonparametric 
analog was employed for cell culture and in vivo studies 
involving two independent groups. 
For the animal studies, sufficient sample sizes were uti-
10 lized to provide at least 80% power to detect large effect 
sizes (1.0 to 3.0 mean differences in SD units) based on 
two-group comparisons, two-sided tests with 5% signifi-
cance level. Some experiments including body weight and 
food intake were measured repeatedly thus affording larger 
15 statistical power. No replicate samples from in vitro studies 
were excluded in the analysis. All data from animal samples 
with measurement of study endpoints were included in the 
analysis. Experiments with slight differences in animal num-
bers per group were due to the number of animals that were 
20 successfully bred and not due to exclusion of certain animals 
and their data points. Mice within a cage were randomized 
to all groups in an experiment to ensure balance in treatment 
group assigmnents across all cages. The animals were ran-
domly selected for group assigmnent without preference to 
25 size or other confounding factors. A different individual 
performed measurements on study endpoints to ensure 
blinding from group assignment. Furthermore, only animal 
IDs without information on group assignment were available 
to staff performing the endpoint evaluation. Parametric tests 
30 were utilized after evaluating distribution of data ( e.g. 
percentiles, mean and median levels), test for normality ( e.g. 
Kolmogorov-Smimov test, if sufficient sample sizes) and 
test for homogeneity of variance assumptions across groups. 
Otherwise, nonparametric tests were utilized. Appropriate-at each time point for other endpoints from in vivo experi-
ments involving repeat measurements. Specifically, body 
weight growth curves were compared using linear mixed 
models with fixed effects for linear and quadratic terms for 
time and their interaction with genotype and random effects 
for the intercept and time factors. Contrast statements for the 
interaction terms in the model were used to assess differ- 40 
35 ness of other statistical models including linear mixed 
models to evaluate trends over time and goodness of fit of 
the models using the Akaike Information Criterion (AIC) 
and analysis of covariance (ANCOVA) assuming equal 
slopes between groups were also evaluated. 
All subjects at the MDC-CC baseline examination were 
divided into ascending quartiles according to their value of 
fasting pro-NT. Body-mass-index (BMI), waist circumfer-
ence and homeostasis model assessment of insulin resistance 
(HOMA-IR) were analyzed as dichotomous outcome vari-
ences in growth curves between genotypes. Likewise, linear 
mixed models were employed for body weight growth curve 
comparisons between vehicle versus SR 48692 with the 
same fixed and random effects terms as above along with 
baseline weight as a covariate. Total food consumption for 
22 weeks was calculated and compared between genotypes 
and between vehicle versus SR 48692 treatment using 
two-sample t-tests. Furthermore, weekly food intake levels 
were analyzed using linear mixed models. However, since 
there is no clear trend in weekly food intake over time, an 
overall comparison of trend was not employed. Instead, a 
linear mixed model with fixed effects for genotype, time and 
their interaction and a random effect for the intercept term 
was employed in order to perform individual comparisons at 
each time point. A p-value adjustment due to multiple testing 
45 ables as defined above. In cross-sectional analyses, the 
present inventors related baseline quartile of pro-NT to the 
dichotomous outcome of obesity, abdominal obesity, and 
insulin resistance using age and sex adjusted logistic regres-
sion models. In the analyses of incident obesity, the present 
50 inventors related baseline quartile of pro-NT to the dichoto-
mous outcome of incident obesity using logistic regression 
adjusted for baseline age, sex, and BMI. Data are presented 
as odds ratios (95% confidence intervals), and subjects 
belonging to the lowest quartile of pro-NT were defined as 
55 the referent group (odds ratio=!). 'P for trend' denotes the 
P-value for linear trend over quartiles 1-4. at each time point was performed using the Holm's step-
down procedure. We used the Akaike Information Criterion 
(AIC) to evaluate the goodness-of-fit of the above linear 
mixed models. One-way or two-way analysis of variance 
models with test for interaction between two factors was 60 
employed for multiple group comparisons of diet (LFD, 
HFD), mouse genotype, feeding and fasting groups, differ-
ent time points of measurement, and varying doses of NT 
treatment, SR 48692 and AI CAR treatments with contrasts 
generated to perform pairwise comparisons. Analysis of 65 
covariance was employed to compare genotype and diet 
with adjustment for the confounding effect of mouse body 
Results: 
To examine the potential role of NT in fat deposition and 
obesity, the present inventors initially compared NT-defi-
cient mice to their wild type littermates fed a standard diet 
(18% kcal from fat) for 6 months. Average body weights, 
body length, small bowel weight and length, villus height, 
and crypt number did not differ significantly between geno-
types (FIG. llA-F). However, at necropsy, the epididymal 
and retroperitoneal fat pads of NT_;_ mice were consistently 
smaller in size as compared to wild type (FIG. 4A-C), which 
prompted further investigation. Indeed, when challenged 
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with a high-fat diet (HFD; 60% kcal from fat), the size of 
epididymal, retroperitoneal, and pericardiac fat deposits 
were markedly smaller in NT-1- mice compared to wild type 
(FIG. 4D-F). Consistent with these differences in fat depo-
sition, as compared to wild type, both male and female 5 
NT_;_ mice fed HFD gained less body weight with signifi-
cant differences first noted at 9 weeks in males (FIG. lA) 
and 16 weeks in females (FIG. 1B). In contrast, no differ-
ences in body weight were noted between female NT+!+ and 
NT_;_ mice fed a low-fat diet (LFD; 10% kcal from fat) 10 
(FIG. 4G), similar to what was observed in mice fed 
standard chow. Echo MRI assessment of total fat ( corrected 
26 
noted in the mucosa of the proximal intestine of NT_;_ mice 
at 30 and 60 min after olive oil gavage compared with NT+/+ 
mice (FIG. 2B). To better track and quantify intestinal 
absorption, 13C18-oleic acid (1
3 C18-OA) was administered 
by gavage and measured in the proximal intestine and 
plasma by Fourier transform-mass spectrometry (FT-
MS). 13C18-OA was significantly decreased in the proximal 
intestine and at 2 and 3 h in plasma of NT_;_ mice compared 
to wild type (FIG. 2C). NT administration (3600 nmol/kg 
body weight, i.p.) restored TG accumulation in NT-1- mice 
to levels similar to those in Nr1+ mice (FIG. 2D). NT 
treatment also increased FA uptake in rat intestinal epithe-
lial- I (RIE-1) cells (FIGS. 7A-B) that express NTRl and 3 
by body weight) further confirmed that body fat composition 
was reduced in NT_;_ mice fed either a HFD or LFD 
compared with wild type (FIG. 4H). 
Obesity-associated insulin resistance was also attenuated 
15 [similar to human intestinal cells (FHs 74 INT) and mouse 
intestinal mucosa (FIGS. 6A-C)], while siRNA knockdown 
of either NTRl or NTR3 reduced NT-mediated FA absorp-
tion (FIG. 7C). 
in NT-deficient mice. On a HFD, NT-deficient mice dem-
onstrated lower levels of fasting plasma glucose and insulin 
(FIG. lC), greater insulin sensitivity, and faster glucose 
20 
clearance (FIG. lD), as compared with wild type. Addition-
ally, insulin-stimulated p-Akt expression was decreased in 
the livers of NT+/+ mice fed HFD, whereas the induction of 
p-Akt following injection of insulin in NT-1- mice fed HFD 
was similar to that noted for both wild type and NT-deficient 
25 
mice fed LFD (FIG. 12A). In contrast, there was no differ-
ence in insulin secretion comparing NT+!+ and NT_;_ mice 
maintained on a normal chow diet following either glucose 
administration by gavage or refeeding after a 16 h fast 
(FIGS. 12B-C). Moreover, hepatic steatosis (assessed by 
30 
H&E and oil red O staining) (FIG. lE) and liver triglyceride 
(TG) and cholesterol accumulation (FIG. lF) were signifi-
cantly decreased in NT-1- mice fed a HFD. Analysis of 
adipocytes in epididymal fat pads showed a reduction in size 
(FIG. lG-H), and decreased inflammatory infiltrates (FIG. 
35 
41) and numbers of macrophages (F4/80-positive cells) 
(FIG. 4J) in NT-deficient mice fed a HFD. These results 
indicate that NT-deficiency protects against many of the 
comorbidities associated with high dietary fat intake. 
Similarly, pretreatment of C57BL/6 mice with SR 48692 
(2.5 mg/kg, ip ), a selective nonpeptide NTRl antagonist that 
acts peripherally and centrally when administered either ip 
or by gavage, decreased intestinal FA absorption following 
olive oil gavage (FIG. 13A). To further demonstrate that the 
effect of SR 48692 was due to disruption of NT signaling, 
the experiment was repeated using NT_;_ mice and their wild 
type littermates. As with the C57BL/6 mice, pretreatment 
with SR 48692 inhibited intestinal FA absorption in wild 
type mice (as measured by TG accumulation). However, SR 
pretreatment in NT_;_ mice did not further decrease lipid 
absorption after olive oil administration which, as expected, 
was significantly decreased compared to wild type mice 
(FIG. 13B). These results indicate that SR 48692 attenuation 
of fat uptake reflects the disruption of normal NT signaling 
and is not due to an unanticipated off-target effect. Consis-
NT has been linked to hypothalamic leptin signaling and 
40 
is considered an anorectic peptide based on acute suppres-
sion of food intake in rats following intracerebral or intra-
peritoneal (i.p.) administration of NT or NT agonists. When 
considering total food intake over 22 weeks, there were no 
differences between genotypes in either male or female mice 
fed with LFD or males fed a HFD; however, a slight 10% 
decrease in female NT_;_ mice fed a HFD reached signifi-
cance (FIG. SA). Weekly food consumption was not statis-
tically different in male or female mice fed with LFD or 
males fed with HFD (FIGS. SB-C); only week 9 comparison 
tent with a role for NT in RFD-induced weight gain, 
treatment with SR 48692 (2.5 mg/kg, oral gavage, twice a 
day) for 13 weeks significantly attenuated body weight gain 
in wild type mice fed a HFD (FIG. 13C) without altering 
food intake (FIG. 13D). Collectively, these results indicate 
that NT promotes intestinal lipid uptake through NTRl and 
possibly NTR3 promoting weight gain in mice fed a HFD. 
45 Interestingly, Rabinowich et al. recently demonstrated that 
NTR3/sortilin deficient mice, when placed on a HFD, exhib-
ited a similar phenotype as NT-deficient mice, thus further 
emphasizing the potential importance of the NT /NTR axis in 
weight gain associated with an overabundance of fat. 
50 
AMPK, a key fuel-sensing enzyme and a critical regulator 
in females fed HFD reached significance (FIG. SC). Energy 
expenditure, locomotor activity, energy intake, and respira-
tory exchange ratio (FIGS. SD-G) did not differ significantly 
between NT+!+ and NT_;_ mice fed either HFD or LFD. 55 
of metabolism, mediates the effects of a variety of hormones. 
Phosphorylated-AMPK (p-AMPK) was upregulated in the 
proximal intestinal mucosa of NT_;_ mice fed a standard 
diet, as compared to wild type mice (FIG. 2E). Alternatively, 
p-AMPK expression was decreased in the proximal intestine Therefore, these factors do not appear to contribute to the 
lower weight gain observed in NT-1- mice fed a HFD. 
The present inventors next evaluated differences in intes-
tinal lipid absorption as a possible mechanism for the 
decreased weight gain noted in NT-deficient mice. Fecal TG 
content was increased by 25% in NT_;_ mice fed HFD 
compared to NT+!+ littermates (FIG. 2A), but was not 
of NT+!+ mice after olive oil gavage, although pretreatment 
with SR 48692 restored the p-AMPK expression to control 
levels (FIG. 2F). Treatment of FHs 74 Int and RIE-1 cells 
60 with oleate also led to an increase in p-AMPK (FIG. 2G), 
while pharmacological activation of AMPK with AICAR 
(5-aminoimidazole-4-carboxamide- l-~-D-ribofuranoside) 
further increased oleate-stimulated p-AMPK (FIG. 2J) and 
concomitantly decreased FA absorption (FIG. 2K). How-
ever, NT pretreatment of the FHs 74 INT and RIE-1 cells 
associated with a change in stool color, consistency or output 
(FIG. 2A), indicating that NT deficiency decreases lipid 65 
absorption without overt signs of fat malabsorption (i.e., 
steatorrhea). Similarly, less and smaller lipid droplets were reduced the p-AMPK increase from oleate (FIG. 2H; FIG. 
US 10,473,670 B2 
27 
7D) and blocked the effects from pharmacological activation 
of AMPK with AI CAR. Conversely, either NTRl or NTR3 
knockdown (FIG. 21, FIG. 7E) prevented the NT-mediated 
suppression of p-AMPK. Knockdown of the upstream 
AMPK kinase Ca2+-calmodulin-dependent protein kinase 5 
kinase (CaMKK2), but not liver kinase Bl (LKBl), 
decreased oleate-stimulated p-AMPK (FIG. 2L). Moreover, 
overexpression of CaMKK2 attenuated NT-mediated sup-
pression of p-AMPK (FIG. 2M). Together, these findings 10 
suggest that NT, acting through NTRl and/or NTR3 
increases FA absorption through suppression of CaMKK2~ 
mediated AMPK phosphorylation. Furthermore, These find-
ings identify AMPK as a critical regulator of NT release 
(throughAMPK activation) and NT-mediated fat absorption 15 
(through AMPK inhibition). 
Drosophila provide a powerful model system to better 
understand molecular mechanisms regulating human meta-
bolic disorders. To further establish the role of NT on 
intestinal lipid absorption and AMPK regulation, the present 
20 
inventors expressed human NT in the midgut EE cells of 
Drosophila using the EE cell-specific drivers Gr36C-Gal4 
(see colocalization with EE-specific transcription factor 
Prospero; FIGS. SA-B) or voila-Gal4. As shown in FIGS. 25 
9A-C, mature NT1 - 13 peptide was detected in larval gut (3.1 
fg/gut) and Drosophila S2 cells transfected with NT cDNA. 
Compared to control, NT expression markedly increased 
lipid droplets in midgut of 7 d adult (FIG. 3A) and larvae 
(FIG. SC) fed a standard diet. Increased lipid droplets were 
30 
also noted in oenocytes (FIG. 3B) and fat body (FIG. 3C) of 
Gr36C-NT 3rd instar larvae. Next, the present inventors used 
a diet-induced obesity model in Drosophila to further delin-
eate the effect of NT in lipid absorption. Increased lipid 35 
droplets were noted in the midgut of wild type flies fed HFD 
compared with flies fed normal food (FIG. 3D). NT expres-
sion dramatically increased lipid accumulation in the midgut 
(FIG. 3D) and total body TG levels (FIG. 3E) with either 
normal food or HFD compared with wild type, suggesting 
40 
that the role of NT is to promote efficient lipid absorption, 
which is further enhanced by increased fat concentration. 
Consistently, the present inventors also found that NT 
expression decreased gut p-AMPK levels in both Droso- 45 
phila adult and larvae (FIG. 3F; FIG. SD). Together, these 
findings suggest that similar to mice, the effects of NT on 
lipid absorption are mediated, in part, through AMPK regu-
lation. Indeed, the present inventors found that AMPK 
overexpression decreased, whereas AMPK knockdown 
50 
increased lipid droplets in the midgut of7 d adults (FIG. 3G) 
and the midgut, fat body and oenocytes of larvae (FIGS. 
SE-G). 
To identify the endogenous Drosophila NTR among the 
many G-protein coupled receptors, the present inventors 
carried out a targeted RNAi screen in cultured Drosophila 
S2 cells; expression of NT or treatment with NT peptide 
consistently decreased p-AMPK (FIGS. lOA-B). Among the 
three potential Drosophila NTRs, RNAi of CG9918 (Pyro-
kinin 1 receptor, PKl-R), but not CG8784 or CG8795 
blocked the decrease in p-AMPK levels in NT-expressin~ 
cells (FIG. lOA), suggesting that NT inhibits p-AMPK 
activation through PK-IR in S2 cells. This effect does not 
appear to be due to interference with PK-1 signaling, since 
PK-1 (encoded by Capability) knockdown did not alter 
55 
60 
65 
28 
p-AMPK levels (FIG. lOC). Knockdown of PKl-R expres-
sion in ECs using MyolA-Gal4 to drive UAS-CG9918 
RNAi (TRiP 27539) expression in flies also expressing NT 
driven by the EE cell-specific tachykinin (TK) promoter 
markedly attenuated NT-induced lipid droplet accumulation 
(FIG. lOD). These results indicate that NT increases lipid 
accumulation, at least in part, through PKl-R, an NTR-like 
receptor that shares a high degree of sequence similarity 
(e.g., 32% identity and 50% similarity) with mouse NTRl 
(FIG. lOE), supporting an evolutionarily conserved function 
for NTR signaling in lipid storage. 
The mouse and Drosophila data prompted the instant 
inventors to assess the possible role of NT in the develop-
ment of obesity and its metabolic complications in humans. 
Fasting plasma concentrations of pro-NT were analyzed 
from 4,632 middle-aged subjects of the population-based 
Malmo Diet and Cancer Study Cardiovascular Cohort (Table 
1). The age- and sex-adjusted likelihood of being obese, 
abdominally obese, and insulin resistant significantly 
increased across quartiles of pro-NT plasma levels (p=0.01, 
0.001 and <0.0001, respectively, Table 2). Continuous val-
ues of pro-NT were also significantly related to continuous 
values of body-mass-index (BMI), waist circumference and 
homeostasis model assessment of insulin resistance (Table 
3). Among non-obese subjects, the risk of developing obe-
sity during an average follow-up time of 16.5±1.5 years 
increased gradually with pro-NT quartiles, independently of 
baseline body mass index (BMI), age, and gender 
(p<0.0001, Table 2). Importantly, non-obese subjects in the 
top quartile of baseline pro-NT levels had greater than 
double the risk of developing obesity compared to those in 
the lowest quartile (OR=2.05, 95% CI: 1.38-3.06). Whereas 
the cross sectional relationship between pro-NT and obesity 
became non-significant after additional adjustment for insu-
lin resistance, the prospective relationship between pro-NT 
and risk of new-onset obesity remained highly significant 
(p=0.001) after adjustment for insulin resistance (data not 
shown). Likewise, the top versus bottom quartiles of pro-NT 
were associated with an OR=l.34 (95% CI: 1.05, 1.70) for 
the risk of being obese, abdominally obese (OR=l.30, 95% 
CI: 1.09-1.54), and insulin resistant (OR=l.70, 95% CI: 
1.39-2.06). Thus, pro-NT levels strongly predict new onset 
obesity in a graded manner, which is independent of baseline 
BMI and insulin resistance. 
TABLE 1 
Clinical characteristics of the Malmo 
Diet and Cancer Cardiovascular Cohort (MDC-CC) 
Characteristic Value N 
Age (years) 57.7 ± 6.0 4,626 
Female sex, n (%) 2661 (57.5) 4,626 
Body Mass Index (kg/m2 ) 25.8 ± 3.9 4,626 
Waist circumference (cm) 84.0 ± 12.9 4,625 
Fasting blood glucose (mM) 5.2 ± 1.4 4,468 
Fasting insulin concentration (mU/L) 7.0 (4.0-9.0) 4,468 
HOMA-IR 1.5 (0.9-2.2) 4,468 
Data_ are giv~n as mea!1 ± standard devi_atior:i for_normally distributed variables, and as 
median and mterquart1le range for fastmg msulm concentration. Categorical data are 
presented as numbers (percentages). 
"N" denotes the number with complete data, thus, included in analyses. 
HOMA-I~ Homeos_tasis Model Assessment of Insulin Resistance (fasting plasma insulin 
concentrat10n x fastmg blood glucose concentration/22.5). 
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TABLE 2 
Fasting plasma concentration of pro-neurotensin (pro-NT) in relation to obesity, 
insulin resistance and incidence of new-onset obesity in hwnan subjects (Malm0 Diet 
and Cancer Cardiovascular Cohort, MDC-CC) 
Odds ratio (95% confidence interval) 
N total/N Pro-NT Pro-NT Pro-NT Pro-NT P for 
Cases Quartile 1 Quartile 2 Quartile 3 Quartile 4 trend 
Prevalent 4626/604 1.0 (ref) 1.00 1.13 1.34 0.01 
obesity (0.78-1.29) (0.88-1.45) (1.05-1.70) 
Prevalent 4625/1769 1.0 (ref) 1.07 1.23 1.30 0.001 
abdominal (0.90-1.27) (1.04-1.46) (1.09-1.54) 
obesity 
Prevalent 4468/1140 1.0 (ref) 1.30 1.43 1.70 <0.0001 
insulin (1.06-1.59) (1.17-1.74) (1.39-2.06) 
resistance 
New-onset 2594/333 1.0 (ref) 1.41 1.79 2.05 <0.0001 
obesity (0.95-2.10) (1.21-2.65) (1.38-3.06) 
N total/N cases denotes total number of subjects in the analysis divided by the number of cases with listed 
obesity or insulin resistance phenotype. 
Pro-NT Quartiles 1-4 define the MDC-CC population quartiles (lowest to highest) with median (range) 
baseline fasting plasma pro-NT concentrations (pmoliL) of60.l (3.3-75.9), 89.3 (75.9-105), 123 (105-149) 
and 190 (149-1155), respectively. 
Data are presented as odds ratios (95% confidence intervals), and subjects belonging to the lowest quartile 
of pro-NT were defined as the reference group (odds ratio= 1). 
P for trend denotes the P-value for linear trend over quartiles 1-4. 
TABLE 3 
Linear regression models to assess association between continuous 
values of log-transformed fasting plasma concentration of pro-
neurotensin (pro-NT) (expressed as per 1 SD increment) in relation 
to continuous outcome values of body mass index, waist circwnference 
and HOMA-IR in human subjects (Malmo Diet and Cancer 
Cardiovascular Cohort, MDC-CC) 
Metabolic trait 
Body Mass Index (per kg/m2 ) 
Waist Circumference (per cm) 
HOMA-IR (per mmol/L*mU/L) 
13-coefficient ± SE 
(per SD increment of 
log-transformed pro-NT) 
0.14 ± 0.06 
0.33 ± 0.15 
0.13 ± 0.G15 
HOMA-IR= Homeostasis Model Assessment of insulin resistance; 
SD = standard deviation; 
SE = standard error; 
pro-NT = pro-neurotensin 
p-value 
0.016 
0.026 
<0.001 
25 FFAR4, is regulated by a novel cross-talk mechanism 
between the AMPK/mTORCl/ERKl/2 signaling pathways 
in intestinal endocrine cells. 
Oleic Acid, a Long Chain FFA, Activates AMPK and 
30 
Stimulates NT Secretion. 
To better delineate the role of FF As in NT secretion, it was 
first determined whether administration of FFAs in vivo 
stimulated NT release. As shown in FIG. 14A, fasting 
plasma NT levels were significantly increased after gavage 
35 ofolive oil (00) (enriched in oleic acid [OA]) (10 µ1/g body 
weight) compared to control mice given saline. Next, it was 
determined whether FFAs stimulate NT secretion using 
intestinal endocrine cell models that our laboratory has 
extensively utilized in the past. These include BON, which 
40 the instant inventors have shown synthesizes and secretes 
NT peptide in a manner analogous to that of N cells in the 
small bowel and QGP-1, a human somatostatinoma cell line 
which expresses high levels of NT and secretes NT in 
response to stimulation. Similar to in vivo study, treatment 
45 with OA stimulated NT secretion (measured by an NT 
enzyme immunoassay [HA]) in both BON and QGP-1; in 
addition, OA treatment increased phosphorylation of AMPK 
(p-AMPK) and acetyl-CoA carboxylase (p-ACC, a down-
stream effector of AMPK) (FIGS. 14B-C). 
The present inventors' findings demonstrate a causative 
role of NT in high fat diet-induced obesity that involves 
decreased AMPK activation and increased intestinal lipid 
absorption. Moreover, the present inventors identify 
increased pro-NT levels as a strong risk factor of human 
obesity, suggesting possible novel avenues of drug devel-
opment research to either prevent or treat this disorder. From 
50 
an evolutionary perspective, metabolically "thrifty" genes, 
Treatment with Agonists to FFAR 1 and 4 Increase AMPK 
Activity. 
like NT, are highly beneficial to ensure the efficient absorp-
tion of all ingested fats, but with the abundance of fats in 
typical Western diets, NT can have a detrimental effect by 
contributing to increased fat storage, obesity, and related 
metabolic disorders. 
Example 2 
A better understanding of the molecular mechanisms 
regulating NT secretion is required to delineate the effects of 
NT during physiologic and pathologic conditions. The 
instant inventors have shown that activation of AMPK 
stimulates NT secretion from endocrine cells through the 
inhibition of mTORCl and negative feedback activation of 
ERKl/2. This example is directed towards showing that 
FFA-mediated NT secretion, acting through FFARl and/or 
FFARl (previously known as GPR40) and FFAR4 (pre-
viously known as GPR120) are medium- to long-chain FFA 
G-protein-coupled receptors that have been implicated in the 
55 regulation of energy homeostasis and hormone secretion. 
The instant inventors have found that the mouse intestinal 
endocrine cell line STC-1, which expresses both FFARl and 
FFAR4 and has been utilized as a model to study FFA-
stimulated hormone secretion, contains an abundant amount 
60 of NT vesicles as noted by immunofluorescent (IF) staining 
using an anti-NT antibody (FIG. 15A, left panel). Either OA 
(0.25 mM) or phorbol myristate acetate (100 nM) (PMA, a 
positive control) treatment stimulated NT release from 
STC-1 cells (FIG. 15A, middle panel). Interestingly, treat-
65 mentwitheither FFARl and FFAR4 agonists (1 µM, 90min) 
or OA increased p-AMPK expression (FIG. 15A, right 
panel), suggesting the possibility that FFA-stimulated NT 
US 10,473,670 B2 
31 
release andAMPK activation are mediated by FFARl and/or 
FFAR4 signaling. Expression ofFFARl and FFAR4 mRNA 
in BON and QGP-1 cells was confirmed by real time-PCR 
analysis (FIG. 15B), further suggesting the involvement of 
both receptors in FFA-regulated NT secretion. 
32 
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Cross-Talk of AMPK, mTORCl and ERK Signaling. 
AMPK activation inhibits mTORCl through raptor, a 
component of mTORCl, or TSC2, a negative regulator of 
mTORCl signaling. The instant inventors have demon-
strated that inhibition of mTORCl signaling enhanced NT 10 
release through feedback activation of ERKl/2 and further-
more, AMPK activation increased NT secretion through 
inhibition of mTORCl signaling (FIG. 16A). Consistently, 
treatment of BON cells with AICAR, an AMPK activator, 
15 
decreased expression of p-S6Kl, a downstream effector of 
mTORCl, and increased p-ERKl/2 (FIG. 16B, left panel). 
Pretreating cells with compound C (CC), a selective AMPK 
inhibitor, attenuated this effect (FIG. 16B, right panel). 
Moreover, a stable BON overexpression cell line was gen- 20 
erated with a mutant raptor vector in which both Ser722 and 
Ser792 (AMPK phosphorylation sites) are replaced by ala-
nine. As shown in FIG. 16C, AICAR-stimulated NT secre-
tion was decreased in cells expressing the mutant raptor 
compared to the cells expressing control vector and treated 25 
with AICAR. Additionally, as shown in FIG. 16D, siRNA-
mediated knockdown ofTSC2 preventedAICAR-stimulated 
NT secretion. Together, these findings further indicate the 
interaction of AMPK, mTORCl and ERK signaling in the 
regulation of NT secretion. 30 and its role in whole-body energy homeostasis. Curr Opin 
Cell Biol 33C, 1-7 (2014). In view thereof, without wishing to be bound by theory, 
it is believed that FFA-mediated NT release by EE cells, 
through a cross-talk mechanism involving AMPK activa-
tion, mTORCl inhibition, and ERKl/2 activation, promotes 
intestinal absorption of FFAs acting through NTRl and/or 35 
NTR3 and the inhibition of intestinal AMPK. Moreover, it 
is believed that the overconsumption of dietary fats, which 
leads to excess NT secretion, results in obesity (from con-
tinued fat storage) and metabolic disorders ( e.g., hepatic 
steatosis and insulin resistance). 
Throughout this document, various references are men-
tioned. All such references are incorporated herein by ref-
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<211> LENGTH, 345 
<212> TYPE, PRT 
35 
<213> ORGANISM, Mus musculus 
<400> SEQUENCE, 1 
Ser Gly Asn Ser Ser Glu Ser Ile Leu 
1 5 
Val Asn Thr Asp Ile Tyr Ser Lys Val 
20 25 
-continued 
Glu Pro Asn Ser Asn Leu Asp 
10 15 
Leu Val Thr Ala Val Tyr Leu 
30 
Ala Leu Phe Val Val Gly Thr Val Gly Asn Ser Val Thr Ala Phe Thr 
35 40 45 
Leu Ala Arg Lys Lys Ser Leu Gln Ser Leu Gln Ser Thr Val His Tyr 
50 55 60 
His Leu Gly Ser Leu Ala Leu Ser Asp Leu Leu Ile Leu Leu Leu Ala 
65 70 75 80 
Met Pro Val Glu Leu Tyr Asn Phe Ile Trp Val His His Pro Trp Ala 
85 90 95 
Phe Gly Asp Ala Gly Cys Arg Gly Tyr Tyr Phe Leu Arg Asp Ala Cys 
100 105 110 
Thr Tyr Ala Thr Ala Leu Asn Val Ala Ser Leu Ser Val Glu Arg Tyr 
115 120 125 
Leu Ala Ile Cys His Pro Phe Lys Ala Arg Thr Leu Met Ser Arg Ser 
130 135 140 
Arg Thr Lys Lys Phe Ile Ser Ala Ile Trp Leu Ala Ser Ala Leu Leu 
145 150 155 160 
Ala Val Pro Met Leu Phe Thr Met Gly Leu Gln Asn Arg Ser Ala Asp 
165 170 175 
Gly Gln His Pro Gly Gly Leu Val Cys Thr Pro Thr Val Asp Thr Ala 
180 185 190 
Thr Val Lys Val Val Ile Gln Val Asn Thr Phe Met Ser Phe Leu Phe 
195 200 205 
Pro Met Leu Ile Ile Ser Ile Leu Asn Thr Val Ile Ala Asn Lys Leu 
210 215 220 
Thr Val Met Val His Gln Ala Ala Glu Gln Gly Arg Gly Val Cys Thr 
225 230 235 240 
Val Gly Thr His Asn Ser Leu Glu His Ser Thr Phe Asn Met Ser Ile 
245 250 255 
Glu Pro Gly Arg Val Gln Ala Leu Arg His Gly Val Leu Val Leu Arg 
260 265 270 
Ala Val Val Ile Ala Phe Val Val Cys Trp Leu Pro Tyr His Val Arg 
275 280 285 
Arg Leu Met Phe Cys Tyr Ile Ser Asp Glu Gln Trp Thr Thr Phe Leu 
290 295 300 
Phe Asp Phe Tyr His Tyr Phe Tyr Met Leu Thr Asn Ala Leu Phe Tyr 
305 310 315 320 
Val Ser Ser Ala Ile Asn Pro Ile Leu Tyr Asn Leu Val Ser Ala Asn 
325 330 335 
Phe Arg Gln Val Phe Leu Ser Thr Leu 
340 345 
<210> SEQ ID NO 2 
<211> LENGTH, 360 
<212> TYPE, PRT 
<213> ORGANISM, Drosophila melanogaster 
<400> SEQUENCE, 2 
36 
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37 
-continued 
Ala Gly Asn Met Ser His Asp Leu Gly Pro Pro Arg Asp Pro Leu Ala 
1 5 10 15 
Ile Val Ile Pro Val Thr Val Val Tyr Ser Leu Ile Phe Ile Thr Gly 
20 25 30 
Val Val Gly Asn Ile Ser Thr Cys Ile Val Ile Lys Lys Asn Arg Ser 
35 40 45 
Met His Thr Ala Thr Asn Tyr Tyr Leu Phe Ser Leu Ala Ile Ser Asp 
50 55 60 
Phe Leu Leu Leu Leu Ser Gly Val Pro Gln Glu Val Ser Tyr Ile Trp 
65 70 75 80 
Ser Lys Tyr Pro Tyr Val Phe Gly Glu Tyr Ile Cys Ile Gly Arg Gly 
85 90 95 
Leu Leu Ala Glu Thr Ser Ala Asn Ala Thr Val Leu Thr Ile Thr Ala 
100 105 110 
Phe Thr Val Glu Arg Tyr Ile Ala Ile Cys His Pro Phe Leu Gly Gln 
115 120 125 
Ala Met Ser Lys Leu Ser Arg Ala Ile Arg Ile Ile Val Leu Val Trp 
130 135 140 
Ile Met Ala Ile Val Thr Ala Ile Pro Gln Ala Ala Gln Phe Gly Ile 
145 150 155 160 
Glu His Tyr Ser Gly Val Glu Gln Cys Gly Ile Val Arg Val Ile Val 
165 170 175 
Lys His Ser Phe Gln Leu Ser Thr Phe Ile Phe Phe Leu Ala Pro Met 
180 185 190 
Ser Ile Ile Leu Val Leu Tyr Leu Leu Ile Gly Val His Leu Tyr Arg 
195 200 205 
Ser Thr Leu Val Glu Gly Pro Ala Ser Val Ala Arg Arg Gln Gln Leu 
210 215 220 
Lys Ser Val Pro Ser Asp Thr Ile Leu Tyr Arg Tyr Gly Gly Ser Gly 
225 230 235 240 
Thr Ala Met Ser Phe Asn Gly Gly Gly Ser Gly Ala Gly Thr Ala Gly 
245 250 255 
Leu Met Gly Gly Ser Gly Ala Gln Leu Ser Ser Val Arg Gly Arg Leu 
260 265 270 
Asn His Tyr Gly Thr Arg Arg Val Leu Arg Met Leu Val Ala Val Val 
275 280 285 
Val Cys Phe Phe Leu Cys Trp Ala Pro Phe His Ala Gln Arg Leu Ile 
290 295 300 
Ala Ile Tyr Ala Pro Ala Arg Gly Ala Lys Leu Arg Asp Gln His Glu 
305 310 315 320 
Phe Val Tyr Thr Val Met Thr Tyr Val Ser Gly Val Leu Tyr Tyr Leu 
325 330 335 
Ser Thr Cys Ile Asn Pro Leu Leu Tyr Asn Ile Met Ser His Lys Phe 
340 345 350 
Arg Glu Ala Phe Lys Ala Val Leu 
355 360 
<210> SEQ ID NO 3 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 3 
38 
tcatcgcctt tgtggtctgc t 
<210> SEQ ID NO 4 
<211> LENGTH, 21 
<212> TYPE, DNA 
39 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 4 
tggttgctgg acacgctgtc g 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 5 
gtctcctcag cttcatcgta t 
<210> SEQ ID NO 6 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 6 
tccccaaagc ctgaagctgt a 
<210> SEQ ID NO 7 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 7 
agaatggtcg agactatgtt g 
<210> SEQ ID NO 8 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 8 
aagagctatt ccaagaggtc c 
<210> SEQ ID NO 9 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 9 
gagaagcccc caaaattctc 
<210> SEQ ID NO 10 
<211> LENGTH, 20 
<212> TYPE, DNA 
US 10,473,670 B2 
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-continued 
21 
21 
21 
21 
21 
21 
20 
41 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 10 
caaggaccca gtgcaggtat 
<210> SEQ ID NO 11 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 11 
actcgctcat cttcgcattt 
<210> SEQ ID NO 12 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 12 
tgggaccaca cgaagttgta 
<210> SEQ ID NO 13 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 13 
tttcaagctg tgctttgtgg 
<210> SEQ ID NO 14 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 14 
agttctctga acgggagcaa 
<210> SEQ ID NO 15 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 15 
tcaccaactg ggacgacatg 
<210> SEQ ID NO 16 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 16 
accggagtcc atcacgatg 
US 10,473,670 B2 
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-continued 
20 
20 
20 
20 
20 
20 
19 
<210> SEQ ID NO 17 
<211> LENGTH, 20 
<212> TYPE, DNA 
43 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 17 
gagtttcaac ggcggaggaa 
<210> SEQ ID NO 18 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 18 
agcagaggaa gaagcacacc 
<210> SEQ ID NO 19 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 19 
ggcgtgctgg gtaatcttat 
<210> SEQ ID NO 20 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 20 
caaaggttgt acagctcctg 
<210> SEQ ID NO 21 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 21 
gctacgccct catatttatc 
<210> SEQ ID NO 22 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 22 
gaggttatag aggtcctgcg 
<210> SEQ ID NO 23 
<211> LENGTH, 18 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
US 10,473,670 B2 
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-continued 
20 
20 
20 
20 
20 
20 
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45 46 
-continued 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 23 
atgaaatcta tgttggtc 
<210> SEQ ID NO 24 
<211> LENGTH, 17 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 24 
ccaacgcgcg ggaaggc 
<210> SEQ ID NO 25 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 25 
gcgtcggtca attcaatctt 
<210> SEQ ID NO 26 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, PCR primer 
<400> SEQUENCE, 26 
aagctgcaac ctcttcgtca 
What is claimed is: 
1. A method of predicting increased risk of obesity in a 
non-obese subject, comprising: 
(a) obtaining a biological sample from the non-obese 
subject; 
(b) detecting an amount of neurotensin in the biological 
sample; 
( c) detecting the phosphorylation level of adenosine 
monophosphate-activated protein kinase (AMPK) in 
the biological sample; 
40 
18 
17 
20 
20 
7. The method of claim 1, wherein the obesity is prevalent 
obesity. 
8. The method of claim 1, wherein the obesity is prevalent 
abdominal obesity. 
9. The method of claim 1, wherein the obesity is new-
onset obesity. 
45 
10. A method of predicting increased risk of obesity in a 
non-obese subject, comprising: 
(a) obtaining a biological sample from the non-obese 
subject; 
( d) determining that the subject has an increased risk of 
obesity if there is an increased amount of neurotensin 50 
and a decreased amount of AMPK phosphorylation in 
the sample as compared to normal levels; and 
(b) detecting an amount of neurotensin in the biological 
sample; 
( c) detecting the phosphorylation level of adenosine 
monophosphate-activated protein kinase (AMPK) in 
the biological sample; ( e) administering an effective amount of a neurotensin 
inhibitor; wherein the neurotensin inhibitor is an NTRl 
antagonist. 
2. The method of claim 1, wherein the neurotensin is 
pro-neurotensin. 
3. The method of claim 2, wherein the amount of pro-
neurotensin is detected by a technique comprising RNA 
measuring assays and protein measuring assays. 
4. The method of claim 3, wherein the RNA measuring 
assay comprises real time reverse transcription polymerase 
chain reaction. 
5. The method of claim 1, wherein the risk of becoming 
obese is independent of baseline body mass index. 
6. The method of claim 1, wherein the biological sample 
comprises blood, plasma, serum, plasma, and tissue. 
55 
60 
( d) determining that the subject has an increased risk of 
obesity if there is an increased amount of neurotensin 
and a decreased amount of AMPK phosphorylation in 
the sample as compared to normal levels; and 
( e) administering an effective amount of a neurotensin 
inhibitor; wherein the neurotensin inhibitor is a non-
peptide NTRl antagonist. 
11. The method of claim 10, wherein the neurotensin is 
pro-neurotensin. 
12. The method of claim 11, wherein the amount of 
pro-neurotensin is detected by a technique comprising RNA 
65 measuring assays and protein measuring assays. 
13. The method of claim 10, wherein the risk of becoming 
obese is independent of baseline body mass index. 
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14. The method of claim 10, wherein the biological 
sample comprises blood, plasma, serum, plasma, and tissue. 
15. The method of claim 10, wherein the obesity 1s 
prevalent obesity. 
16. The method of claim 10, wherein the obesity IS 
prevalent abdominal obesity. 
17. The method of claim 10, wherein the obesity IS 
new-onset obesity. 
* * * * * 
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